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1. INTRODUCTION 
 
Siddha system of medicine is the most ancient medical science which is 
propounded and practised by eminent spiritual scientists called Siddhars. Siddhars are 
those who lived and maintained their bodies as they desired best. They had realised that, 
the body though transient was one and only instrument for attaining success in the 
spiritual development and growth and so worked out to attain the eight super natural 
powers the Ashtamasiddhi, essential for their goal. 
In Siddha system of medicine a close relation is maintained between man and 
prabancham (The Universe). What ever changes occur in the Prabancham, influences the 
human body also. It has been illustrated as, 
“AiPj§p Es[úR ©iPm 
©iPj§p Es[úR AiPm 
AiPØm ©iPØm Juú\ 
A±kÕ Rôu TôodÏmúTôúR” 
- NhPØ² Oô]m. 
Our unique system is based upon two main theories viz 
1. The Panchabootha Theory. 
2. Tridhosa Theory 
1. Panchabootha theory of universe, 
“¨Xm ¿o ¾ Y° ®ÑmúTôûPkÕm 
LXkR UVdÏm EXLUôR­u” 
- ùRôpLôl©Vm. 
2. Panchabootha theory of man 
“RXeLôh¥«ÚkRf NPUô] ûYméRm 
¨XeLôh¥ ¿oLôh¥ ¨u±Úk ¾Lôh¥ 
YXeLôh¥ YôÙYôp Y[okúR «ÚkR 
ÏXeLôh¥ Yô²t Ï¥Vô«ÚkRúR 
CÚk§Óªq ûYkRôùXÓjR NPªÕ” 
- §ÚêXo Sô¥ 
 2 
 
3. Tridhosa Theory of Universe, 
YôRUôn TûPjÕ ©jR Yu²Vôn LôjÕ úNhT 
ºRUôn ÕûPjÕ TôWôk úRLj§tÏ¥Vô ûUkÕ 
éR®k§VôûUYo éûN ùLôiPYo Tôp ®kÕ 
SôRUôm ¡Úh¥Q êoj§ SUdùLußm ÕûQVôYôúW 
- úRWu UÚjÕ TôWRm 
4. Tridhosa Theory of man 
“ùR°kÕ®hP Sô¥VÕ Oô]m úTôúX 
£\lTô] ×¬êuß ùUôu\ôn á¥ 
ùUô¯k§hP YôR©jR £úXtT]ùUuß 
ØuûL«p éi¥ÚdÏ Øû\ûUVôL” 
- NRL Sô¥ 
Sô¥ : 
EP­p E«o R¬j§ÚkÕ CVeLf ùNnÙm Nd§ GÕúYô AÕúY 
E«oRôÕ. 
These three components when in equilibrium keep the body in homeostasis but 
when vitiated either solely or in combination bring about disease.  
“ª¡àm Ïû\«àm úSôn ùNnÙm èúXôo 
Y°ØRXô Gi¦V êuß.” 
- §ÚdÏ\s 
 Siddha system describes 4448 diseases and its treatment.Balavagadam is one of 
the literature in siddha system of medicine which deals with Pediatric diseases and its 
management. Balavagadam had got more importance than any other branches of medicine 
in Siddha system.  This is evident from the classification of disease from birth to late 
childhood and the various line of treatment with specific herbs which is a distinct feature 
of pediatric Medicine in Siddha. 
Infectious diseases and nutritional deficiencies are the twin problems among the 
health problems of children affecting their growth and development. “Kanam”  is one of 
the commonest infectious disease. 
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Kanam has been classified into 24 types in siddha system. Vali kanam is one 
among them. It affects the upper respiratory tract causing cough, fever, irritation of throat, 
lack of appetite and dysuria. Vali kanam is a disease to give more troublesome in 
childhood (3 to 12 yrs of age group). 
Sathaveri Kirudham is indicated for all types of Kanam. It which posses mainly 
Asparagus Racemosus Linn , Smilax China Linn and Elattera Cardomomum Linn, having 
Antitussive, Antibacterial, Expectorant, Antipyretic, Antimicrobial activites.These drugs 
are  commonly used in clinical practice. Since the formulations have  not undergone any 
clinical trial so far, the author selected Sathaveri Kirudham to evaluate its efficacy in 
the treatment of Valikanam. 
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2. AIM AND OBJECTIVES 
AIM  
To evaluate the efficacy of SATHAVERI KIRUDHAM for the management of 
Valikanam (Upper Respiratory Tract Infection) 
OBJECTIVES  
1. To study the preclinical analytical standardization and safety study of the 
experimental formulation Sathaveri Kirudham  
2. To collect and review the ideas mentioned in the ancient Siddha literature 
about the disease Valikanam.  
3. To explore definition, etiology, clinical features, diagnosis, investigations 
and treatment of valikanam as laid down from various siddha literature  
4. To study the disease Valikanam on the basis of three thodam, 
envagaithervugal, neerkuri, neikuri, udal thathukkal, paruvakaalangal, age, 
sex and economic status.  
5. To make the correlative study of the siddha and modern aspect of this 
disease.  
6. To use the modern parameters in the investigation of the disease that 
enhances to observe the progess of the patient.  
7. To conduct a clinical trial to find out the efficacy of SATHAVERI 
KIRUDHAM To have a detailed analysis of the disease Valikanam 
through the clinical efficacy of the drugs. 
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3. REVIEW OF LITERATURE 
                                           3.1 SIDDHA ASPECT 
                  fzk; 
I.  ,ay;(Definition):           
khjhf;fspd; gpjhf;fspd ehj tpe;Jf;fslq;fpa thjhjp Njh\q;fspdpd;W 
cw;gj;jpahfpf; fUg;ghraj;J rpRitg; gw;wp mr;rpRthdJ VOtif jhJf;fSk; 
td;ikailAq;fhyj;J mij Nehahy; tUe;j nra;Ak; Neha;. 
A congenital disease of the child arising from the maturity of bad humours 
inherited from the parents .It is an atrophy resulting from the enlargement of the bowels. 
This disease progresses in several forms as the child advanges in age. (T.V.Sambasivam 
Pillai) 
fz Nuhfk;: 
Foe;ijfSf;F fzr;#l;bdhYk; ghypd; Fw;wj;jpdhYk; tapW 
Nfhshwile;J clk;gpy; fdg;Gz;lhfpr; Ruk; tpau;it euk;G typ Kjypad 
Vw;gl;L vYk;G FWfp clk;G ,isj;J tUk; Neha;. 
A constitutional disease in children arising from congenital heat or bed nutrition 
resulting in diarrhoea of the stomach and glowing head in the body.It is marked by fever 
sweating of the head,nervous affection of the bones,general emaciation.-  
(T.V..Sambasivam Pillai) 
     rpj;j kUj;Jt E}yhd ghythflk; (Foe;ij kUj;Jtk;);> fzj;jpid %d;W 
tifapy; tiuKiwg;gLj;Jfpd;wJ. mit tUk; topapidg; nghWj;J ,U 
gphpTfSk;> Njhd;Wk; tajpidg; nghWj;J xU gphpTk; MFk.;  
                           fzk ; 
        
        
  tUk;top nghWj;J    3. taijg; nghWj;J 
          (%d;W fUj;Jfs;) 
v 3-7tajpy; cz;lhjy; 
v ghYk;NrhWk;cz;Zk; 
gUtj;jpy; cz;lhjy; 
v 3-12 tajpy; cz;lhjy;        1. fh;g;gr;R+L  2. khe;jNehapd; njhlh;r;rpahf  
                          cz;lhtJ 
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1. fh;g;gr;R+L 
‘njhifahd fzq;fs; vy;yhk; fh;g;gr;R+L”   
- mNahj;jpjhrh; ghythflk;. 
 ‘R+L”vd;gij ‘clypd; ntg;gepiy” vd;W nfhs;Nthkhdhy; fUTw;w 
fhyj;jpy; jha;khh;fSf;F fpUkp njhw;wpdhy; (maternal infection) Ruk; Vw;gl;L> 
mJ gpwf;Fk; Foe;ijiaAk; ghjpg;gjhf nfhs;syhk;.. 
 khwhf ‘R+L” vd;gij gpj;jk; (m) moy; vd caph;j;jhJthf nfhz;lhy;> 
fUtpd; moy;jhJ khWghL fPo;f;fz;l tifapy; cz;lhfyhk;. 
1. fytpapy; Vw;gLk; tpfw;gk;. 
2. Rf;fpy> RNuhzpjq;fspd; tpfw;gk;. 
3. fUTw;w jha;khh;fspd; czTKiw> nray;ghLfs; ,tw;wpd; 
tpfw;gq;fs;. 
1. fytpapy; Vw;gLk; tpfw;gk;: 
vz;nza; Nja;j;J %o;fpagpd;> clNd czT mUe;jp> cwf;fk; 
nfhs;tjhy; clypd; gpj;jNjhlk; mjpfhpf;Fk;. mNj Neuj;jpy;; cwT 
nfhs;Sk;NghJ cz;lhFk; fUTf;F fzk; cz;lhfyhk; vd;W fUjg;gLfpwJ.  
(Eg.) khe;jfzk; - Mjhuk;: ghythflk; 
2. Rf;fpy> RNuhzpjq;fspd; tpfw;gk;: 
fzkhdJ> khjhgpjhf;fsp;d; ehjtpe;Jf;fSs; mlq;fpa thjhjp 
Njhlq;fspypUe;J cw;gj;jpahfp> fUg;igapd; rpRitg;gw;wp> mr;rpRtpdJ 
rg;jjhJf;fSk; td;ikia milAk; fhyj;jpy; ghjpf;fpd;wJ. (Njhlq;fs; tpUj;jp 
milfpd;wd).  
- Mjhuk;: IPtul;rhkph;jk;  
‘Rf;fpyj;jpy; RNuhzpjq; fyf;Fkd;W 
 GFe;jpLk; tpahjp %d;Wk;” 
- jd;te;jphp ehb E}y;. 
fUTf;F moy;jhJtpid Nrh;g;gJ Rf;fpykhFk; mjid gpd;tUk; E}y;fs; 
njspthf $Wfpd;wd. 
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         ”ghd;ik vd;w tpe;jq;Nf A+Wk;NghJ 
          ghAklh td;dpNahL thAjhNd” ; 
- mfj;jpah; ty;yhjp ehb E}y;. 
      ” cd;dpa fh;g;gf; Fopahk; ntspapNy 
 gd;dpa ehjk; gfh;e;j gpUjptp 
 td;dpAk; thAT khapUQ; Rf;fpyk; 
       kd;dpa rkdha; tsh;f;F KjfNk”. 
- jpUke;jpuk;. 
fUtpw;F> tpe;JtpypUe;J - thjk;> gpj;jk; vd ,uz;L jhJf;fSk; cjfePh;> 
ehjk; ,tw;wpypUe;J fgKk; fpilf;fpwJ vd fUjg;gLfpwJ. 
mNj ghlypy;> 
 ‘cjfKjpu KWq;fdy; thAthy; 
  rpj FW kq;fq;fs; nra;J Kbj;jpLk;” 
vd Fwpg;gpLtjhy; 
cjfkhfpa ePh;> jP kw;Wk; thAtpd; jd;ikahy; nre;ePuhf khwp kw;w 
cly;jhJf;fshd Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; ,tw;iw cz;lhf;Fk; 
vd fUjg;gLfpwJ. 
 vdNt Rf;fpy> RNuhzpjq;fspd; FiwghL> cjfePhpd; FiwghL 
Nghd;wtw;why; fUtpd; caph;j;jhJfspy; xd;whd moy; ghjpg;giltjhy; fzk; 
Vw;gLfpwJ. ‘fh;g;gr;R+L’ vd miof;fg;gLtjw;Fk; mJNt fhuzk; vd fUjyhk;.  
3;. fUTw;w jha;khh;fspd; nray;ghLfs;: 
 ‘igau ty;F yhSk; grpAldpUe;j jhYk; 
  Ja;aNjhh; Fotpfl;F fzq;fSe; Njhd;Wkd;Nw”   
                                             - ghythflk;. 
fUTw;w jha;khh;fspd; czT gof;ftof;fq;fs;> nray;ghLfs; 
Nghd;wtw;why; jhapd; clypy; moy;jhJ ghjpg;gile;J mJ fh;ghraj;ijAk; 
jhf;Fk; vd [Ptul;rhkph;jk; vd;w E}ypy; $wg;gl;Ls;sJ. 
 vdNt fUtpd; moy;jhJtpy; FiwghL Njhd;Wtjhy; mjd; cly; 
jhJf;fs; ghjpf;fg;gLfpd;wd. ,JNt ‘fh;g;gr;#L’ vd miof;f fhuzkhfTk; 
mike;jpUf;Fk;.  
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4. khe;j Nehapd; njhlh;r;rpahf fzk; Njhd;Wk; tpjk;: 
khe;jk; :  jha; kw;Wk; Foe;ijfspd; czthjp (m) Fzthjp gof;f 
tof;fj;jpy; Fw;wk; NehpLk;NghJ Foe;ijfSf;F Njhd;Wk; nrhpkhdf; NfhshWfs;> 
mjidj; njhlh;e;j czTg;ghij njhlh;ghd cghijfSk; khe;j Neha; vd;W 
miof;fg;gLfpd;wJ. 
 
czTg;gof;fj;jhy; khe;jk; Njhd;Wjy;: 
 cz;Zk; cztpd; nrhpkhdj;jpw;F> 
 rkhdd;  - thjk;> 
 mdw;gpj;jk; - gpj;jk;> 
 fpNyjfk; - fgk;> 
 Mfpa %d;wpd; ,ay;ghd msT Kf;fpakhdjhFk;. 
mdw;gpj;jk;  - czTg;nghUs;fspd; nrhpkhdj;jpy; Kjd;ik gq;F  tfpf;fpwJ.  
fpNyjfk;   - cz;Zk; cztpid nkj;njd nra;Ak;.  
rkhdd;   - Nkw;fz;l ,uz;ilAk; rkepiygLj;jp> rhpahd    
         nrhpkhdj;jpw;F cjTfpwJ. ,J nrayw;why; nrhpkhdNk elf;fhJ. 
ke;jhf;fpdp: 
Nkw;fz;l %d;wpy; mdw;gpj;jj;jpd; td;ik Fiwe;jhNyh> fpNyjfj;jpd; 
td;ik mjpfhpj;jhNyh> rkhdthA jd; ,aw;if epiyapypUe;J jtwpdhNyh 
ke;jhf;fpdp cz;lhFk;. mjdhy; czTg; nghUl;fs; clNd nrhpg;gpf;fhky;> 
thAthy; taw;wpiur;ry;> Flypiur;ry;> tapw;Wg;gprk; vd;Dk; ,tw;iw cz;lhf;fp 
neLNeuk; fopj;J nrhpg;gpf;;Fk;. vdNt cztpd; rhuk; clYf;F fpilf;fhky; 
Nghfpd;wJ. 
 Nkw;fz;l FiwghLfshy; cz;lhFk; Foe;ijfspd; cly;> kd 
ke;jj;jpid khe;jk ; vd rpj;j kUj;Jtj;jpy; miof;fg;gLfpd;wJ. 
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khe;jk; njhlh;e;J epiyg;gjhy; 
fzj;jpd; FwpFzq;fs; Njhd;Wjy; 
cztpd; rhuk; clw;fl;LfSf;F Nrh;tjpy; njha;T 
Vw;gLfpwJ. (tpahddpd; njhopy; ghjpj;jy;) 
rhuk; nre;ePuhf khWk;; Ntiy ghjpj;jy; 
(,uQ;rf gpj;jj;jpd; njhopy; ghjpj;jy;) 
kw;w clw;fl;Lfis Nghlzpg;gjpy; rpukk; cz;lhjy; 
clw;fl;Lfspd; td;ik Fiwjy; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. fzk; Njhd;Wk; taJ: 
“vd;dNt fz%d;W tUle; njhl;Nl 
Vohz;L kl;Lf;F kpUf;Fq; fhyk;”        
- ghythflk;. 
taijg; nghWj;J %d;W fUj;Jfs;: 
     1. 3-7tajpy; cz;lhjy; 
     2. ghYk; NrhWk; cz;Zk; gUtj;jpy; cz;lhjy; 
  3. 3-12 tajpy; cz;lhjy; 
II. Neha; tUk; top: 
 ‘IaJ $bw; nwd;why;  
            mhpitah; Jaue;jd;dhy; 
  nra;a gw; GdyUe;jpr;  
           nrwpry Njhle;jd;dhy; 
   igau ty;FyhSk;  
            grpAldpUe;jjhYk; 
   Ja;aNjhh; Fotp fl;Ff;  
            fzq;fSe; Njhd;W kd;Nw”. 
- ghythflk;. 
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1. IaJ $bw;nwd;why;: (Iak; - caph; jhJ) 
Iaj;jpd; ,aw;if epiyfs;> mjd; kpFFzk; Nghd;wtw;iw xg;G Nehf;Fk; 
nghUl;L fPo;fz;lthW njhFf;fg;gLfpd;wJ.  
jd;ik:   
­ jz;ik> nea;g;G 
­ ke;jk;> tOtOg;G 
­ nkd;ik> jpz;ik 
thOkplk;: 
­ rkhdthA> ROKid 
­ Mf;fpid> tpe;J 
­ ehf;F> cz;zhf;F 
­ nfhOg;G> kr;ir 
­ FUjp> khh;G 
­ euk;G> vYk;G 
­ %is> ngUq;Fly;> fz;> fPy;fs; 
 
,aw;ifg; gz;G: 
­ epiyj;jy; 
­ nea;g;G  
­ fPy;fspd; mikg;gpd; fl;Lfs; 
­ nghiwAilik ( grp> ePh;Ntl;if Jauk;> fyf;fk;> ntg;gk; 
Nghd;wtw;iw nghWj;Jf; nfhs;Sjy;) 
Ia kpFFzk;: 
­ mf;fpdp ke;jg;gly; 
­ tha;ePH Cwy; 
­ Cf;fk; Fiwjy; 
­ cly; fdkhf Njhd;WtJld; ntz;zpwj;ijAk;>  
   Fsph;r;rpiaAk; miljy;. 
­ cly; Kw;Wk; cs;s fl;Lfs; jsuy; 
­   ,iug;G> cg;gprk;> ,Uky;> kpFJ}f;fk; cz;lhjy;. 
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2. mhpitah; Jaue; jd;dhy;: 
mhpit - ngz;fspd; gUtq;fspy; xd;W. 
20-25 tajhdJ kfsph; kfg;NgW milAk; nghJthd fhyk; vd;gjhy;> 
ghlypy; mhpit vd;w thh;j;ijia Nkw;nfhz;bUg;gij czuyhk;. mg;gUtj;jpy; 
kfsphpd; Jd;gq;fshd cly;eyf;FiwT> nghUshjhuf;FiwT Nghd;wit 
Foe;ijfSf;F gy ,lh;ghl;bidAk;> Fwpg;ghf fzj;jpidAk; cz;lhf;Fk;;. 
3. nra;a gw;GdyUe;jp nrhpry Njhle;jd;dhy;: 
 gy;NtWtifg;gl;l ePhpid mUe;Jtjhy; ryNjhlq;fs; cz;lhfp epiyj;J 
fzNeha; Njhd;Wk; vd;gJ nghUshFk;. 
 mj;jifa ePhpd; jd;ik> Fbj;jYf;F Mfhj ePH vd rpj;jkUj;Jtj;jpy; 
$wg;gl;Ls;s fUj;Jfis fhz;Nghk;. 
ePhpd; jd;ik: (rpj;jkUj;Jthq;f RUf;fk;) 
ePuhdJ kdJf;F fspg;igAk;> epiwitAk; cz;lhf;FtJ kl;Lkd;wp 
cl;nfhs;Sk; cztpid ed;wha; clypw; gutr; nra;J clw;F td;ikiaj; 
jUk;. NkYk; cz;l fbd czTg;nghUl;fis nrhpg;gpf;Fk;.  
ePUf;F jdpFzk; ,y;iy. mJ jq;Fk; ,lj;jpd; NtWghLfshNyNa 
ntt;NtW Fzq;fis milfpd;wJ.,jid>  
‘jz;zPh; Fznky;yhe; jhd; Nfs; klkapNy 
kz;zpd; Fzky;yhy; kw;Wz;Nlh? ’  
- Njud; nghUl;gd;G 
Fspay; Fbj;jYf;F Mfhj ePh;: 
 ‘re;jpuh jpj;jh; tsp rhuhj ePh; GOJh;f;  
  fe;jkjp NrW fdg;gpiyA - jphpe;j ePh; 
  jq;FRit apy;yh ePh; rhw;Wkpit ];ehdgh 
  dq;fSf;fh fhTwpNeh ahk;” 
- gjhh;j;j Fz rpe;jhkzp 
jpq;fs;> QhapW ,tw;wpd; fjpnuhsp;;; fhw;W ,itfs; mZfhjJk;; fpUkp> 
Jh;ehw;wk;> NrW jbj;jy;> rUF cjpuy;> Ritapd;ik vd;Dk; ,itfs; 
nghUe;jpaJk; Mfpa ePh;> Fspay;> Fbj;jy; ,itfl;F MfhJ. ,ij cz;zpd; 
Nehia cz;lhf;Fk; 
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NkYk;> 
‘Jiyahf; fpzNw fae;jpul;Lk; ”  
      - ,iwg;gpy;yh fpzw;WePh; fgg;gpzp cz;lhf;Fk;. 
           ‘tsh;f;FQ; Ruj;ij rU$wy; ”     
    - rUF Cwpa ePh; Ruk; tsh;f;Fk;. 
           ‘khwhf; FsNk tpahjpAz;L ”    
- gad;gLj;jhj Fsj;JePh; tpahjp cz;lhf;Fk;. 
mt;thW gy;NtWgl;l ePhpid mUe;Jtjpdhy; ryNjhlk; Vw;gl;L fzNeha; 
Njhd;Wk; vd;W $wg;gLfpd;wJ. 
4. igau ty;FyhSk; grpAldpUe;jjhYk;: 
(igau - #y;nfhz;l: ty;Fyhs; - #Yw;w ngz;fs;).  
#Yw;w ngz;fs rhptpfpj cztpid cz;zhjjhy; mth;fspd; cly;eyd; 
Fd;wp mJ Foe;ijfspd; tsh;r;rpiaAk; fzNeha; Njhd;Wtpf;Fk.; 
gpw E}y;fs; fUj;J : 
· jpUts;Stehadhh; ,aw;wpa etuj;jpdrpe;jhkzp 800 y; $wpathW 
je;ijapd; Ntl;ifahy; gpz;lk; fdypy; mbgl;L fzk; tUtjhf 
$wg;gl;Ls;sJ. 
 “ghuhd nfw;gntl;il kPUk; gf;Ftj;jpy; 
 Ntuhd tphpe;J ntspg; gl;L Nahdp tpOe;j njd;whw; 
 fhuhd gpz;lq; fdypyb gl;Lf; fhe;jpdpdhw; 
 $uha; fzRu nka;J nkd;Nwahd; $wpNdNk” 
· jd;te;jphp itj;jpak; vDk; E}y; fzkhdJ G+h;tn[d;kq;fspy; nra;j 
jPtpidfis je;ijahfTk;> ,g;gpwg;gpy; nra;Ak; jPtpidfis jhahfTk; 
mile;J “~af; Fkhud;” gpwf;fpwhd; vd;W $WfpwJ. 
           ‘rPhpa njhd;ik nra;j jPtpid je;ijahfg; 
  ghhpypg; gpwg;gpw; nra;j ghtNk jhajhfg; 
  Nghpar; raf; Fkhud; tpwe;jpyh fpw kj;jg;Ng 
  fhhpa nrtpypj; jhaha; ‘fzk;” ngw tsUk; ehspy;….. 
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III. fzj;jpd; tiffs;(Types): 
 gy;NtW E}y;fs; ntt;NtW vz;zpf;iffspy; fzj;jpidj njhFf;fpd;wd. 
1. gps;isg;gpzp kUj;Jtj;jpy; $wg;gl;Ls;s fzq;fs;-64 tiffs; 
1. tspfzk;    33. mow;fzk; 
2. Ia fzk;   34. khe;j fzk; 
3. ePh;f;fzk;    35. gpuspf;fzk; 
4. #ypfzk;    36.. Ropfzk; 
5. kfhfzk;    37. CJfzk; 
6. tus;fzk;   38. nfhjpg;G fzk; 
7. tPf;f fzk;   39. gpwf; fzk; 
8. mf;fu fzk;   40. ke;jhu fzk; 
9. vhp fzk;    41. ePuhk fzk; 
10. ,uj;j fzk   42. Kf;F fzk; 
11. %y fzk;   43. Nguhk fzk; 
12. cyup fzk;   44. rpq;fp khe;j fzk; 
13. Mk fzk;   45. Rj;jp fzk; 
14. czf;F fzk;   46. ru;g;g fzk; 
15. cd;Nuhffzk;   47. rpj;ufzk; 
16. CJkhe;j fzk;   48. Rufzk; 
17. fug;ghd;fzk;   49. jdpRufzk; 
18. fsp;fzk;    50. mjpRu fzk; 
19. Fly;Nrhif fzk;  51. J}q;F fzk; 
20. FlNyw;w fzk;   52. njw;fj;jp fzk; 
21. vhp fzk;    53. njw;fj;J khe;j fzk; 
22. ,uj;j fzk   54. ePuhk;g fzk; 
23. %y fzk;   55. gl;rp fzk; 
24.  kNfe;jpu fzk;   56. ghy fzk; 
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25. ke;jhu fzk;   57. %yhjhu fzk; 
26. Nkf fzk;   58. thA fzk; 
27. thNte;jpu fzk;   59. thyre;jpu fzk; 
     28. tp\ fzk;   60. tp\ePu; fzk; 
     29. tp\ghf fzk;   61. tp\ khe;j fzk; 
     30. tpujp fzk;   62. tPq;F fzk; 
     31. ntg;G fzk;   63. Fd;wp mf;fu fzk; 
     32. nghUK fzk;             64. KbNyhf fzk; 
2. Mj;kul;rhkph;jk; vd;Dk; itj;jpa rhuq;f rq;fpufk;    
  - fe;jrhkp Kjypahh;; 
1. thj fzk;   13. gpj;j fzk; 
2. rpNyj;Jk fzk;   14. khe;j fzk; 
3. ePh;f; fzk;   15. gpusp fzk; 
4. #iyf; fzk;   16. Rop fzk; 
5. kfh fzk;   17. CJ fzk; 
6. twl;rp fzk;   18. nfhjpg;G fzk; 
7. tPf;f fzk;   19. gpwf; fzk; 
8. Mkf; fzk;   20. twl;rp fzk; 
9. Kf;F fzk;   21. Nghh;f; fzk; 
10. ,uj;j fzk;   22. er;R khe;j fzk; 
11. CJ khe;j fzk;   23. vhp fzk; 
12. ke;jhu fzk; 
3.mNahj;jpjhrh; ghythflk; 24 tif - gf;fk; - 180; gjpg;G 1992 
1. tspfzk;     
2. mow;fzk; 
3. Ia fzk;    
4. khe;j fzk; 
5. ePh;f;fzk;     
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6. gpuspf;fzk; 
7. #ypfzk;     
8. Ropfzk; 
9. kfhfzk;     
10. CJfzk; 
11. tus;fzk;    
12. nfhjpg;G fzk; 
13. tPf;f fzk;    
14. gpwf; fzk; 
15. me;jf fzk;    
16. ke;jhu fzk; 
17. vhp fzk;     
18. ePuhk fzk; 
19. Mk fzk;        
20. Kf;F fzk; 
21. %y fzk;    
22. Nguhk fzk; 
23. uj;j fzk;    
24. rpq;fp khe;j fzk; 
4. guuhr Nrfuk; ghyNuhf epjhdk; - 18 tiffs; ghly; : 271; gf;fk;- 75 
1. thj fiz   10. gpj;j fiz 
2. Ruf; fiz   11. mj;jpRu fiz 
3. twl;fiz       12. thyre;jpufiz 
4. kNfe;jpu fiz   13. J}f;F fiz 
5. mdw; fiz   14. tPq;F fiz 
6. ntSg;Gfiz   15. rj;jp fiz 
7. ,uj;j fiz   16. %yf;fiz 
8. fUq;fiz       17. kQ;rl; fiz 
9. epyf; fiz   18. ntg;G fiz 
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5  .gps;isg;gpzp thflk; - 8 tif 
1. ePh; fzk;    5. tus; fzk; 
2. %yfzk;    6. rPjfzk; 
3. ,ja fzk;   7. kfhfzk; 
4. kyf;fzk;   8. Fz;lypa fzk; 
6. [Ptul;rhkph;jk;> 8 tiffs; - MWKfk; gps;is mgpjhd rpe;jhkzp  
1. #ypfzk;    5. Kf;F fzk; 
2. Mkfzk;    6. Njiufzk; 
3. kfhfzk;    7. Ropfzk; 
4. fopfzk;    8. tws;fzk; 
TV rhk;grptk; gps;is mfuhjpapd;gb  
fzkhdJ> khjh gpjhf;fspd; ehj tpe;Jfs;slq;fpa thjhjp 
Njhlq;fspdpd;W cw;gj;jpahfpf; fUg;ghraj;Jr; rpRitg; gw;wp mr;rpRtpdJ 
vOtifj; jhJf;fSk; td;ikailAq; fhyj;J mij Nehahy; tUe;jr; nra;Ak; 
Neha;. 
,J jkpo; itj;jpag; gb Nehapd; Fzk; Fwp ,itfspd; ngahpl;L mNdf 
tpjkha;f; nfhs;sg;gLk;. 
A congenital disease of the child arising from the maturity of the bad humours 
inherited from the parents. It is an atrophy resulting from the enlargement of the bowels 
(tabes mesenterica). The disease progresses in several forms as the child advances in age. 
IV. fzj;jpd; nghJ Fzq;fs; : 
1. ghy thflk; $Wk; Nehapd; Fzq;fs; 
· Foe;ijfSf;F khe;j Neha; gyKiw te;J Kw;wpYk; Fzkilahky; 
,Ug;gjhy; ,e;Neha; cz;lhFk;. 
· gpj;jkhdJ mjpfkhfp thAf;fs; jd; Ntiyia nra;a Kbahky; 
jLj;JtpLk;. mjdhy; Foe;ijfspd; clypy; Vw;gl;l #L ve;NeuKk; 
tplhJ fhZk;. 
· Ruk; fha;jy; 
· ,Uky; 
· %r;R thq;Fjy; 
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· cly; Nrhh;tiljy; 
· tapW Nehjy; 
· tapW fopjy; : 
 
­ kyk; vz;nza; frpthdjhf ,Uf;Fk; 
­ rPjkhf> ,uj;jkhf (m) ,uj;jKk;> rPjKk; fye;J  
Ngjpahjy; 
­ ghy; Nghy ntz;zpwkhf fopjy; 
­ Cz; fOtpa jz;zPh; Nghy; Ngjpahjy; 
­ kytha; vhpr;ry; 
­ kyk; ntl;ilahjy; (kyr;rpf;fy;) : 
 
· cr;rpapy; Fop tpOjy; 
· Kfk; Nrhh;tile;J fhZjy; 
· Fuy; fk;kyhf NgRjy; 
· if> fhy;> Kfk; twz;L fhZk; 
· mdy; tPRtJ Nghd;W cl;Ruk; fhzy; 
· tha;ehw;wk; 
· khh;G $k;G Nghy; vOk;gp fhzy; 
· ePh; RUq;fy; 
fzj;jpy; xd;Wld; xd;W njhlh;Gfsw;w gy FwpFzq;fs; njhFg;ghff; 
fhzg;gLfpd;wd. mjdhy; fzj;jpy; gy Neha; epiyfs; ,Ug;gjid mwpayhk.; 
NkYk; nghJf;FwpFzq;fis gpujhdkhff; nfhz;L> fzj;jpd; rpwg;G 
Fzq;fSld; nghUj;jp (fzj;jpd; tiffs;) Nehapid fzpj;jy; rpwg;ghdjhFk;.  
gpw E}y;fspy; fhZk; fzj;jpd; nghJFzq;fis mwpe;J nfhs;Sk;NghJ> 
Nehapid Fwpj;j njspthd xg;GNehf;F nra;a KbAk; vd;gjhy; mjidAk; 
fhz;Nghk;;. 
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2. mgpjhd rpe;jhkzp $Wk; Nehapd; Fzq;fs;: 
· khh;gpy; tPf;fk; 
· cl;Ruk; 
· Ruk; 
· twz;l kyk; 
 
3.  [Ptul;rhkph;jk ; $Wk; Nehapd; Fzq;fs;: 
· Njfthl;lk; 
· tha;ehw;wk; 
· jiyRw;wy; 
· cs;Ruk; (my;yJ) 
· xU Ntis ntspRuk; (my;yJ) 
· tapw;wpd; Nky; RLjy; 
· kaf;fk; 
· twz;l kyk; 
,f;Fzq;fs; rfy fzj;jpw;Fk; nghJthf tUk; vd mwpf. 
cs;Ruk; Fwpj;j tpsf;fk;: 
mf];jpah; RuE}y; 300 - ‘rpj;jkUj;Jtk; - nghJ’ gf;fk; 57 - 6k; gjpg;G 
vd;w E}ypy; ‘RukNj fizajhFk;” vd $wg;gl;Ls;sJ. 
mjd; tpsf;fj;jpy; Foe;ijfSf;F Njhd;Wfpd;w vd;GRuk;> moy; Ruk;> 
khe;jRuk; Nghd;witfs; Foe;ijfis tUj;jkilar; nra;J> gpd;dh; fiz 
Nehapid gpwg;gpf;Fk;. 
fzk; - Ruk; njhlh;G : 
 ‘fiz Nehapy; cl;Rukhf fhAk;” 
 rpj;jkUj;Jtk; - nghJ 
 ‘fizapy; fhe;js; kyh; Nghd;w Ruk; fhZk;” 
 Nkw;fz;l Nkw;Nfhs;fs;> fzj;jpy; Ruj;jpw;Fk; gpw Neha; epiyfspy; 
fhZk; Ruj;jpw;Fk; NtWghL cz;L vd;gij njspthf $Wfpd;wd. 
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(fhe;js; kyh; vd;gJ jP G+jj;Jld; njhlh;G nfhz;lJ. me;j kyhpd; my;yp 
,jo;fs; RUf;fkhdjhf fhZk.; fiz NehapYk;> njhlh;e;J cl;Ruk; cs;s 
Foe;ijfs; cly; Nrhh;tile;J fhZtjhf nghJ FwpFzj;jpy; Fwpg;gplg;gLtJ 
rpwg;ghFk;). 
‘cl;Ruk;” vd;gJ gpw Ruq;fspypUe;J NtWgl;lJ. ,r;Ruk;> cly; td;ik 
Fiwe;j Ngh;f;F ntspf;F njhpahky; clypd; cs;Ns jfpj;J> Ruk; ,Ug;gJ 
Nghd;W fhzg;gl;L> Nrhfk;> kdj;jsh;r;rp> iffhy; Xa;r;ry;> cztpy; 
tpUg;gkp;d;ik> tha;f;Fkl;ly;> vg;NghJk; Ruk; fha;tJ NghypUj;jy;> cly; 
nkype;J nfhz;Nl nry;Yjy; vd;Dk; Fwp Fzq;fis gpwg;gpf;Fk;. 
        - rpj;jkUj;Jtk; - nghJ - gf;fk; - 36. 
ghythflk; E}ypd;gb tsp fzj;jpd; FwpFzq;fs;: 
“thj fzj;jpd; Fzj;jpay;ig 
      tFg;Nghk; clYk; ghukjha; 
      Nghj ,iuf;Fk; ehtuSk; 
           Gife;Nj ,UKw jhfKld; 
      thj fzj;jpd; Fzj;jpay;ig 
       tFg;Nghk; clYk; ghujkha;g; 
      Ngj khf ePu;r;RUf;fhk;” ; 
· tapW ,iuAk; 
· eh tuSk; 
· Gifr;ry; 
· ,Uky; 
· mjpf jhfk; 
· Ruk; 
· grpapd;ik 
· ePu;r;RUf;F 
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[Ptul;rhkph;jk; - E}ypd; gb tsp fzj;jpd; FwpFzq;fs;: 
Ø tapW ,iuAk; 
Ø eh tuSk; 
Ø Gifr;ry; 
Ø ,Uky; 
Ø mjpf jhfk; 
Ø Ruk; 
Ø grpapd;ik 
Ø ePu;r;RUf;F 
Ø kyk; ,WFk; 
guuhrNrfuk; - ghyNuhf epjhdk; E}ypd; gb tsp fzj;jpd; FwpFzq;fs;: 
    “thj fzj;jpd; Fzj;jpay; tFg;Nghk; clYk; ghukjha; 
     Nghj ,iuf;Fk; ehtuSk; Gife;Nj ,UKw jhfKld; 
     thj fzj;jpd; Fzj;jpay;ig tFg;Nghk; clYk; ghujkha;g; 
     Ngj khf ePu;r;RUf;fhk;” ; 
Ø tapW ,iuAk; 
Ø eh tuSk; 
Ø Gifr;ry; 
Ø ,Uky; 
Ø mjpf jhfk; 
Ø Ruk; 
Ø grpapd;ik 
Ø ePu;r;RUf;F 
Ø kyk; ,WFk; 
V.Neha; fzpg;G: (Diagnosis) 
Piniyari muraimai is a method of diagnosing a disease. Siddha system has a very 
unique method of diagnosis. 
  “Pini” means    =   Disease 
  “Ari” means  = Identify 
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  “Muraimai” means   =   Method. 
This is based upon three main principles and Envagai Thervugal. The three main 
principles are, 
1. Poriyal arithal (Inspection) 
2. Pulanal arithal ( Palpation) 
3. Vinathal ( Interrogation) 
 Physician’s ‘Pori’ and ‘Pulan’ are used as tools for examining the ‘Pori Pulan’ of 
the patients. The above principles correspond to the methodology of  1.Inspection, 
2.Palpation and, 3.Interrogation in modern medicine, in arriving a clinical diagnosis of the 
disease. 
1. Poriyaal arithal: (Inspection) 
Porigal are considered as the five senses of perception namely, 
1. Nose  
2. Tongue   
3. Eye    
4. Skin  
5. Ear 
2. Pulanal arithal: (Palpation) 
  Pulangal are functions of five senses. They are, 
1. Smell  
2. Taste 
3. Vision 
4. Sensation of Touch                                                                                                           
5. Hearing. 
Vinathal: (Interrogation) 
Vinathal is asking the information regarding the history of the disease, its clinical 
feature etc., from the patient or his close relatives who are taking care of him/her.     
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      rpj;j kUj;Jtj;jpd; Neha;fzpg;gpy; gpd;tUk; fhuzpfs; Kf;fpa gq;F 
tfpf;fpd;wd. 
Nehahspiar; rhh;e;jJ 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
2. cly; jhJf;fs; (VO clw;fl;Lfs;) 
3. vz;tifj; Njh;T  
Nehahspiar; rhuhjJ 
4. nghOJ 
rpWnghOJ    - itfiw> tpbay;> vw;ghL> ez;gfy;> khiy  
                ahkk; 
        ngUk;nghOJ  - fhh;> $jph;> Kd;gdp> gpd;gdp> ,sNtdpy;>   
                             KJNtdpy; 
5. Itif epyq;fs; : FwpQ;rp> Ky;iy> kUjk;> nea;jy;> ghiy. 
Nkw;$wpa fhuzpfspd; khWghLfis xd;Wld; xd;W xg;gpl;L Neha; 
fzpf;fg;gLfpwJ. 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
tsp fzj;jpy; Kf;Fw;w tpfw;gk; 
thjk;> gpj;jk;> fgk; Mfpa %d;W jhJf;fspy; rkr;rPH epiyapy; cz;lhFk; 
NtWghLfis Nehahf cw;gj;jpahfpwJ. 
(m)  ‘eLq;fpaNjhh; gpj;jkJ Nfhgq; nfhz;L 
     ey;ythAit gw;wp aOj;jpf; nfhs;Sk;” 
 - ghy thflk; 
Kjypy; gpj;jNjhlk; ghjpg;gile;J (jd;dpiy tsh;r;rp mile;J) gpd;G 
tspFw;wj;jpd; njhopiyAk; (Ntw;Wepiy tsh;r;rp mile;J) ghjpg;gjhf 
nfhs;syhk;. 
 ,Nj fUj;ij ‘ke;jkyhJ thAtuhJ” -; vd;w Njud; Nrfug;gh ghlyhy; 
ke;jj;jpdhy; thA cz;lhFk; vd mwpayhk;. NkYk; khe;jk; (ke;jk;) vd;gJ 
gpj;jj;jpd; jd;dpiy tsh;r;rp Fzk; vd mwpaNtz;Lk;. 
 (M)  ‘IaJ $bw; nwd;why;”                      -  ghy thflk; 
,jd; nghUs; Iaf;Fw;wk; jd;dpiyapy; tsh;r;rp miljy; vd;gjhFk;  
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,Nj fUj;ij ‘fgj;jpidad;wp fhrRthrk; fhzhNj” - vd;w 
Njud;Nrfug;gh ghlyhy; Iaf;Fw;wj;jpd; jd;dpiy tsh;r;rpad;wp fzj;jpd; 
FwpFzkhd fhrk;> Rthrk; tuhJ vd mwpayhk;. moy; Fw;wk; jd;stpy; kpFe;J 
thAit gw;wp mOj;jpf; nfhs;Sk;. mjdhy; clypy; mjpfg;gl;l moy; 
jzptjw;F topapy;yhky; Foe;ijf;F mjpfkhf #L cz;lhfp cly; fdfdg;G 
Vw;gLfpd;wJ. 
(2) tsp fzj;jpy; cly;jhJf;fspd; epiy: 
cz;lcztpd; md;drhukhdJ Flypy; cwpQ;rg;gl;L clw; jhJf;fshd 
rhuk;> nre;ePh;> Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; (m) RNuhzpjk; 
Nghd;wtw;iw Nghlzpf;fpd;wJ vd cly;jj;Jt E}y;fs; $Wfpd;wd. 
 ‘je;jpL euk;g njy;yhe; jhq;fpNa A+izg; gw;wp 
 ce;jpL kpuj;jnky;yh kKnjd Tz;Z kd;Nw” 
  - guuhrNrfuk; - ghyNuhf epjhdk; ghly;: 269 
vd;w ghlyhy; fiz Neha; cly; jhJf;fis ghjpf;Fk; vd mwpayhk.; 
fizapy; cly; jhJf;fs; Nghlzpf;fg;gLtjpYk;> cUthf;fj;jpYk; rpukk; 
Vw;gLfpwJ vd;gjhy; Neha; jPtpuj;jpw;F Vw;g midj;J jhJf;fSk; (Rf;fpy> 
RNuhzpjk; cs;gl) thpirahf xd;wd;gpd; xd;whf ghjpg;gilAk; vd 
fUjg;gLfpwJ. Rf;fpyk;> RNuhzpjk; ,tw;iw Neubahf tpe;J> ehjk; vd;W 
nghUs; nfhs;shky;> cly; nry;fs; kw;Wk; cWg;Gfs; jd;idnahj;j cUtg; 
ngUf;fpw;F Kjyha; epw;Fk; cly; jhJ vd nghUs; nfhs;tJ rpwg;ghFk;.  
(3) tsp fzj;jpy vz;tifj; Njh;Tfs;: 
nghwp> Gyd;fshy; mwpjy;> tpdhjy; Nghd;witfspd; %yk; kUj;Jth; 
mwpe;jtw;iw vz;tifj; Njh;Tfs; %yk; cWjpgLj;j Ntz;Lk;. 
 ‘ehb ];ghprk; eh epwk; nkhop tpop 
 kyk; %j;jpukpit kUj;JtuhAjk;” 
- Neha;ehly; Kjy; ghfk;        
     ’Njba tpahjpf; nfy;yk; Njfj;jpy; ghpl;irAz;L 
 $bNa epw;Fnkl;L ghpl;irahq; $wf;NfsPh; 
 ehbNa njhl;lhw; Njfk; %j;jpuk; thh;j;ij fz;fs; ehf;F 
 ghbNa kyryq;fs; gy tz;zk; ghh;j;Jf; nfhs;Ns” 
      -  rpj;j kUj;Jtkzpfs; 
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Nkw;$wpa ghlypd; %yk; ehb> ];ghprk;> eh> epwk;> nkhop> tpop> kyk;;> 
%j;jpuk; Mfpad kUj;Jthpd; MAjk; Nghd;wit vd mwpayhk;. 
1. ehb 
vz;tifj; Njh;Tfspy; gpujhdkhdJ. gpzpapid ehbahywpe;J 
kUe;J}l;LjNy rpwe;jJ vd;W rpj;j kUj;Jtk; $Wfpd;wJ. Mdhy; Foe;ijfspy; 
ehbeil rhpahf Njhd;whJ vd;gij fPo;fz;l ghlyhy; mwpayhk;. 
 ’nfhz;blNt faNuhfp fhrNuhfp 
 Fwpg;ghf rpw;wpd;gk; nra;j Ngh;fs; 
 mz;blNt jhpj;jpuh;fs; tpUj;jh; ghyh; 
 nfhz;blNt ,th;fspd; cWg;gpd; jhJ 
 $wNt KbahJ vth;f;Ff; fpl;Lk;.” 
- Neha;ehly; Neha; Kjy;ehly; jpul;L 
vdpDk; fzj;jpy; gpj;jFw;wk; Kjd;ikahf ghjpj;J gpd; thj> fg 
Fw;wq;fSk; ghjpg;gjhy;> fPo;fz;l ehbeilahdJ Njh;thsuhy; ghpNrhjpj;J 
vOjg;gl;lJ. 
- gpj;jfgk; 
- gpj;jthjk; 
-  thjgpj;jk; 
2. ];ghprk;: 
Nehahspapid njhl;L ghh;j;jypd; %yk; czug;gLk; FwpFzq;fs; MFk.; 
tsp fzNehapy; fPo;f;fhZk; FwpFzq;fs; mt;thW czug;gl;lJ. 
- tapWtyp;> Ruk;> cl;Ruk; 
3. eh 
 Nehahshpd; ehf;fpid ghh;j;J czug;gLk; fzNehapd; FwpFzq;fshtd. 
- nre;ePh;j;jhJ Fiwe;J fhZjiy> eh ntspwpl;L ,Uj;jyhy; mwpayhk;. 
4. epwk;: 
 tspfzNehapy; clw;fl;Lfs; td;ik Fiwe;Js;sij mwpa 
epwg;ghpNrhjid gad;gLk;. 
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Njhypd; epwk;  -  ntspwpf;fhZjy; 
       fWj;Jf;fhZjy; 
 eh> fz;  -  ntspwpf;fhZjy; 
5. nkhop: 
tspfzNeha; Foe;ijfspy; fgk; mjpfhpf;Fk; fhuzj;jhy; Fuy;fk;ky; 
Njhd;wp jho;e;J NgRth;. 
6. tpop: 
 tpopr;Nrhjidapy;> fzNehapd; fPo;f;fhZk; FwpFzk; czug;gl;lJ. 
- fPopik ntspwpf;fhZjy; 
7. kyk;: 
 fzNeha; Foe;ijfspy;> tpdhjypd; %yk fPo;fz;l FwpFzq;fs;mwpayhk;. 
- fopr;ry; 
- kyr;rpf;fy; 
8. %j;jpuk;: 
tspfzNehapy ePu;r;RUf;F fhzg;gl;lJ. 
Foe;ijfspy; Ngjp ,Ue;jhy; clypd; ePh;j;Jtk; Fiwe;J ePh;;;;;;;tuj;J 
Fiwe;J fhZk;. 
9. ePh;f;Fwp: 
  ‘te;j ePh; fhpnail kzk; Eiu vQ;rnyd; 
   iwe;jpaYsit aiwFJ KiwNa” 
    - Neha; ehly; Kjy; ghfk; 
 ePhpy; epwk;> kzk;> Eiu> vil> vQ;ry;> Mfpatw;iw Nehf;f Ntz;Lk;. 
nea;f;Fwp: 
Foe;ijfspd; ehbeil rhpahf fzpg;gjpy; rpukk; cs;sjhy;> nea;f;Fwp 
ghpNrhjid %yk; Nehahsh; vf;Fw;wj;jhy; ghjpf;fg;gl;Ls;shh; vd;gjid 
fzpf;fyhk;. 
 fzNehahspapd; rpWePiu Nrhjid tl;bypy; Cw;wp xsp kpFe;j ,lj;jpy; 
ePhpd; miyapy;yhj NghJ ey;nyz;nzaj;;Jsp tp;l;L ghh;f;fg;gl;lJ. 
rpyhpy; Mop Nghy; (Nkhjpuk;) gutpAk;> rpyhpy; Kj;JNghy; epd;Wk; 
fhzg;gl;lJ. 
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 ‘muntd ePz;bd; thjk; 
 MopNghw; gutpd; gpj;;jk; 
 Kj;njhj;J epw;fpd; nkhoptnjd; fgNk” 
- Neha; ehly; Kjy; ghfk; 
kUj;Jtk; 
1. Ntw;Wepiy tsh;r;rpaile;j gpj;jj;jpid jd;dpiyg;gLj;j Ntz;Lk; 
2. jd;dpiy tsh;r;rpaile;j Iaj;jpid rkg;gLj;j Ntz;Lk; 
3. gpj;jFw;wj;jhy; ghjpg;gile;Js;s thjj;jpidAk; rhpg;gLj;j Ntz;Lk;. 
4. td;ik ,oe;j clw;fl;Lfis td;ik milar;nra;Ak; tifapy; 
kUe;jspf;f Ntz;Lk;. 
Keeping in mind the need for bringing out an effective therapy for Vali Kanam 
from Siddha system of Medicine, the author has taken this clinical study with Sathaveri 
kirudham. 
The dosage of medicines are  
3 to 12 years – 6 to 10ml b.d 
VI. Line of Treatment: 
 Siddha treatment is not only for complete healing but also prevention and 
rejuvenation. Saint Thiruvalluvar says about physician’s duty, study the disease, study the 
cause, treat subsiding way and do what is proper and effect. 
 ‘Neha; ehb Neha; Kjy; ehb mJ jzpf;Fk; 
 tha;ehb tha;g;gr; nray;. 
 ‘cw;whd sTk; gpzpasTq; fhyKq; 
 fw;whd; fUjpr; nray;.” 
    - jpUf;Fws; 
 So it is essential to know the disease, the etiology, the nature of patients, severity 
of the illness, the seasons and the time of occurrence. 
Line of treatment is as follows. 
1. Kaappu (Prevention) 
2. Neekkam (Treatment) 
3. Niraivu (Restoration) 
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1. Kaappu (Prevention):  
Prevention and cure of the diseases are the basic principle of any medical system, 
but prevention is the main aim of Siddha system. Siddhars have described general 
preventive measures and special measures. (Which are applicable to diseases of certain 
organs) 
            And especially in Balavagadam, the preventive measures are explained in detail. 
Prevention of the disease of the child starts from the conception and goes on as the child 
grows up in intra uterine life and after delivery.  Siddhars have dealt elaborately with the 
diet of pregnant women, her habit, the medicine to be taken in every month, her 
psychological conditions, and surroundings etc. 
2. Neekam: (Treatment) 
The aim of treatment is based on, 
a. To bring the three thodams into normal equilibrium state, emetics and purgatives 
are given. But considering physical condition of the children administration of 
purgatives and emetics is excluded from line of treatment. 
b. To treat the patient according to the symptoms by internal medicine “Sathaveri 
kirudham”. 
3.  Niraivu: (Restoration) 
1. Reassurance of disease recovery was given to all patients. 
2. All the patients are advised to follow the life style that provides a disease free 
life.  
Pathiyam (Diet): 
 During the course of treatment, the drug is administered to the patients according 
to the nature of disease and the patients were advised to follow certain restrictions 
regarding diet and physical activities. 
 This type of medical advice in siddha system of medicine is termed as 
“Pathiyam”. 
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Importance of pathiyam is quoted as follows. 
     ‘gj;jpaj;jpdhNy gyDz;lhFk; kUe;J 
 gj;jpaq;fs; Nghdhy; gyd; NghFk; - gj;jpaj;jpy;  
 gj;jpaNk ntw;wpjUk; gz;bjHf;F Mjypdhy; 
 gj;jpaNk cj;jpnad;W ghH”                     - 
NjiuaH ntz;gh 
The patient with Vali Kanam advised to avoid cool drinks, cold water and 
exposure to chill weather and allergens (dust and odours)  
 During the course of treatment according to the drug administered to the patients 
and nature of the disease, the patients were advised to follow certain precautions 
regarding diet and physical activities. This type of medical advice in Siddha system of 
medicine is termed as Pathiyam.  
Siddhars advice regarding the diet regimen for Kaba patients is explained below: 
Siddhars advised to avoid certain food items in Kaba and Pitha noigal. They are 
given  below:  
fj;jhp 
Nga;Gly 
tiu 
ghfy; 
fsh 
mj;jpf;fha; 
gPHf;;fqfha; 
fjypj; jz;L 
Ks;sq;fp 
fUk;G 
g+rpdpf;fha 
cs;sp 
 
 ‘fj;jhp Nga;Gly tiu apUghfy; gUq;fsh fz;lfhhp 
 mj;jpf; fha;fSk; tUf;ifkhgaw;iw fiuahy; gPHf;fUk; -    
              gpQ;RNtH 
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 nkha;j;j R+uzq; fjypj; jz;Lfisg; g+Ksq;fp KUf;fUk;Gk; 
 mj;jpg; g+rpdpf; fhaUs;sp ts;spAq; fgj;NjhHf; fhzkhNk” 
‘Ntis kzj;jf;fhsp nkd; rPij rf;utHj;jp 
 gPis triy Rf;F ngz;Rzq;fs; - Ntisapiy 
 nre;jspH fisf; fPiu nra;tH fgNjfH epjk; 
 te;jdpAzj;jhd; kfpo;e;J” 
- gjhHj;j Fz rpe;jhkzp 
Prevention methods: 
 The patients were advised, 
Ø To find out which agent makes allergy and avoid them. 
Ø To avoid contaminated food and water. 
Ø To avoid cold weather. 
Ø To avoid cold food stuffs, beverages etc. 
Ø To take highly nutritious diet like vegetable soups to get their immunity 
developed. 
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3.2  MODERN ASPECTS 
RESPIRATORY TRACT: 
The anatomical structure through which air moves in and out is the respiratory 
tract. It consists of Nose, Nasal cavity, pharynx, larynx, trachea, bronchi and lung tissue. 
There are 2 tracts of the respiratory system: 
Upper respiratory system  
Lower respiratory system  
                                
 
UPPER RESPIRATORY TRACT: 
It Consist of the nose, nasal cavity, paranasal sinuses, and the pharynx (throat) 
LOWER RESPIRATORY SYSTEM  
It is composed of small airways called respiratory branchioles, alveolar ducts and 
alveoli (air sacs) 
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ANATOMY OF THE UPPER RESPIRATORY TRACT: 
 
The Nose: 
This is the main conducting airway which is supported with many bones and 
cartilage. 
The Nasal Cavity: 
Contains "internal nares" which connect the nasal cavity to the paranasal sinus.  
This cavity is lined with pseudostratified ciliated columnar epithelium and coarse 
hairs near the vestibule (cavity near the nostrils) called vibrissae which protect the lungs 
from large particles and bacteria. 
The superior, middle and inferior nasal conchae subdivide the nasal cavity into 
three separate air pathways called the nasal meatus which is responsible for the main 
functions of gas conditioning.  
The Paranasal Sinuses: 
The paranasal sinuses contain sinuses from all the surrounding bones and are 
named accordingly: the frontal, ethmoidal, sphenoidal and maxillary sinuses. 
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All the sinuses communicate with the nasal cavity and their functions are to 
cleanse air, serve as chambers for sound resonance and lighten the weight of the skull.  
They are all line with the same pseudostratified ciliated columnar epithelium 
lining as the nasal cavity. 
The Pharynx: 
  Commonly called the throat, it is used for inhalation/exhalation and swallowing 
food. Posterior to the nasal and oral cavities and extends inferior towards the lower 
respiratory tract. 
It contains skeletal muscles and flexible walls also coated with mucus for 
protection.  
It is split into three regions: the Nasopharynx, Oropharynx and Laryngopharynx. 
Nasopharynx: 
The most superior region of the pharynx and is directly posterior to the nasal 
cavity and superior to the soft palate which forms a seal from the oral cavity.  
On the lateral walls of the nasopharynx a pair of auditory tubes connects the 
Nasopharynx to the middle ear. This is to relieve pressure from the ear drum through the 
nasopharynx. 
Oropharynx:   
 Immediately posterior to the oral cavity.  
Laryngopharynx: 
This area is the inferior narrowed region of the pharynx. The area covered by this 
region is from the inferior part of the hyoid bone to the superior part of the esophagus. 
This region is also lined with non-keratinized stratified squamous epithelium for 
protection. 
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COMMON UPPER RESPIRATORY TRACT INFECTION:   
The Upper respiratory tract includes the nasal passages sinuses pharynx, larynx, 
which serves as gateways to the trachea, bronchi, and pulmonary alveolar spaces. 
Upper respiratory tract infections represents the most common acute illness 
evaluated in the clinical setting. URTIs range from common cold typically a mild self 
limited cattarhal syndrome of nasopharnyx to life threatening illnesses such as epiglottis. 
Viruses account for most URIs. Bacteria primary infection or superinfection also causes 
URTIs. 
URIs is specifically manifested as cough, fever, Rhinitis, Pharyngitis, Epiglottis, 
Laryngitis and Tracheitis. 
DEFINITION:  
Upper respiratory tract infections (URI or URTI) are the illnesses caused by an 
acute infection which involves the upper respiratory tract: nose, sinuses, pharynx or 
larynx. This commonly includes: tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media 
and the common cold. 
COMMON URI TERMS ARE DEFINED AS FOLLOWS: 
Ø Rhinitis : 
Inflammation of nasal mucosa 
Ø Rhinosinusitis/Sinusitis :  
Inflammation of the nares and paranasal sinuses including frontal, 
ethmoid, maxillary and sphenoid. 
Ø Rhino Pharyngitis (Naso Pharynitis): 
Inflammation of the nares, pharynx, hyp[opharnyx, uvula and 
tonsils. 
Ø Pharyngitis:  
Inflammation of Pharnyx , hypopharnyx 
Ø Epiglossitis(Supraglossitis): 
Inflammation of superior portion of larynx and supraglottic  area. 
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Ø Laryngitis 
Inflammation of Larnyx 
Ø Laryngo Tracheitis: 
Inflammation of larynx trachea and subglottic area 
Ø Tracheitis: 
   Inflammation of trachea and subglottic area 
MODE OF TRANSMISSION: 
 The mechanisms of viral transmission are not well established, but most 
respiratory infection are thought to be spread by hand contamination with infectious 
secretions and subsequent auto-inoculation (nose-to-hand-to-hand-to-nose). Aerosol 
transmission and fomite transmission are also possible; prompt disposal of nasal 
secretions and handwashing are recommended interventions.  
ETIOLOGY: 
Viral  Cause: 
Thefollowing viruses can cause upper respirator tract infection 
· Adenovirus: 
Adenoviruses are nonenveloped DNA virus with diameter of 70 to 90 nm and 
spherical Icosahederal symmetry. Grown in tissue cultures if human origin.eg:Human 
amnion HeLa Around 33 serotypes are identified which causes infection. It causes 
infection of respiratory tract, intestine, eye. 
· Rhinovirus: 
Rhinoviruses are over 100 serotypes of which H strain infects the human.It mainly 
causes infection of the upper respiratory tract and sometimes infects gastrointestinal tract 
also. 
· Paramyxovirus 
Paramyxoviruses are RNA viruses spherical or filamentous in shape 00 to 200 nm 
in size. 
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· Corynovirus 
 Coranoviruses are ellipitical or spherical or filamentous enveloped with 
lipoprotein. 
· Reovirus 
Reo viruses are ether resistant icosahederal with double stranded RNA and causes 
mild respiratory and enteric diseases. 
Reoviruses are spherical 50 to 80 nm in diameter 
Bacterial Cause: 
· Staphylococci: 
Staphylococci are gram positive cocci, ovoid, non motile bacteria producing 
enterotoxin. Their deep infection produces sinusitis,tonsillitis, (upper respiratory 
infection) 
· Streptococci 
· Pseudomonas 
· Klebsiella 
They are found in the mucous of the upper respiratory tract and intestine. They are 
non motile, capsulated grows in ordinary media forming colonies. 
Fungal cause: 
Fungal are the normal inhabitants of the respiratory tract can also produce illness. 
· Candida produces upper respiratory illness (Laryngitis) in 
immunocompromised individuals. 
COMMON CLINICAL FEATURES OF UPPER RESPIRATORY TRACT 
INFECTIONS: 
· Cough- mild to moderate , hacking cough 
· Nasal discharge- common 
· Nasal congestion , Sneezing, sore throat 
· Fever – slight, present in children 
· Head ache 
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· Myalgia- slight 
· Conjunctivitis occurs with adenoviral infections 
· Fatigue 
· Weakness 
· Malaise 
PATHOPHYSIOLOGY: 
URIs involve direct invasion of the mucosa lining the upper airway. Person-to-
person spread of viruses accounts for most URIs. Patients with bacterial infections may 
present in similar fashion, or they may present with a superinfection of a viral URI. 
Inoculation by bacteria or viruses begins when secretions are transferred by touching a 
hand exposed to pathogens to the nose or mouth or by directly inhaling respiratory 
droplets from an infected person who is coughing or sneezing.  
After inoculation, viruses and bacteria encounter several barriers, including 
physical, mechanical, humoral, and cellular immune defenses. Hair lining the nose filters 
and traps some pathogens. Mucus coats much of the upper respiratory tract, trapping 
potential invaders. The angle resulting from the junction of the posterior nose to the 
pharynx causes large particles to impinge on the back of the throat. Ciliated cells lower in 
the respiratory tract trap and transport pathogens up to the pharynx; from there they are 
swallowed into the stomach.  
Adenoids and tonsils contain immune cells that respond to pathogens. Humoral 
immunity (immunoglobulin A) and cellular immunity act to reduce infections throughout 
the entire respiratory tract. Resident and recruited macrophages, monocytes, neutrophils 
and eosinophils coordinate to engulf and destroy invaders. A host of inflammatory 
cytokines mediates the immune response to invading pathogens. Normal nasopharyngeal 
flora, including various staphylococcal and streptococcal species, help defend against 
potential pathogens. Patients with suboptimal humoral and phagocytic immune function 
are at increased risk for contracting a URI, and they are at increased risk for a severe or 
prolonged course of disease.  
Viral agents include a vast number of serotypes, which undergo frequent changes 
in antigenicity, posing challenges to immune defense. Pathogens resist destruction by a 
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variety of mechanisms, including the production of toxins, proteases, and bacterial 
adherence factors, as well as the formation of capsules that resist phagocytosis.  
Incubation times before the appearance of symptoms vary among pathogens. 
Rhinoviruses and group A streptococci may incubate for 1-5 days, influenza and 
parainfluenza may incubate for 1-4 days and respiratory syncytial virus (RSV) may 
incubate for a week. Pertussis typically incubates for 7-10 days or even as long as 21 days 
before causing symptoms. Diphtheria incubates for 1-10 days. The incubation period of 
Epstein-Barr virus (EBV) is 4-6 weeks.  
Most symptoms of URIs, including local swelling, erythema, edema, secretions 
and fever, result from the inflammatory response of the immune system to invading 
pathogens and from toxins produced by pathogens. 
 An initial nasopharyngeal infection may spread to adjacent structures, resulting in 
sinusitis, otitis media, epiglottitis, laryngitis, tracheobronchitis, and pneumonia. 
Inflammatory narrowing at the level of the epiglottis and larynx may result in a dangerous 
compromise of airflow, especially in children, in whom a small reduction in the luminal 
diameter of the subglottic larynx and trachea may be critical. Beyond childhood, 
laryngotracheal inflammation may also pose serious threats to individuals with congenital 
or acquired subglottic stenosis.  
RHINITIS: 
Causes of Rhinitis: 
· Rhinovirus,  
· Enterovirus 
· Coronavirus 
· Influenza A and B virus 
· PIV, RSV, and Adenovirus.  
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Symptoms of Rhinitis: 
It is a inflammatory disorder marked by clear rhinorrhoea, malaise low or 
moderate fever nasal congestion. 
Examination reveals pale and edematous nasal mucosa congested nasal turbinates 
and nucoid rhinorrhoea. 
Conjunctival itching and redness are sometimes present. 
Children are affected on average of six to eight of these upper respiratory 
infections every year.     
RHINOSINUSITIS: 
Inflammation of the nares and paranasal sinuses including frontal, ethmoid, 
maxillary and sphenoid. 
The term "common cold" refers to acute Nasopharyngitis (sometimes called acute 
rhinosinusitis), a mild, self-limited syndrome caused by viral infection of the upper 
respiratory tract mucosa. Cardinal features include malaise, nasal discharge and 
obstruction, sneezing and sore or "scratchy" throat. 
· Viral causes:  
· Rhinovirus,  
· Enterovirus 
· Coronavirus 
· Influenza A and B virus 
· PIV, RSV and Adenovirus.  
· Bacterial causes: 
· Streptococcus pneumonia,    
· H influenza  
· Moraxella catarrhalis.  
· Other important pathogens include Group A streptococci and other 
streptococcal species. 
· Uncommon causes include C pneumonia, Neisseria species, 
anaerobes, and gram-negative rods.  
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Symptoms of Rhinosinusitis: 
· Mucopurulent secretions: These may be present in the nares with both viral and 
bacterial sinusitis. Secretions may be thick or yellow.  
· Nasal discharge: This may be persistent and purulent, and sneezing may occur. 
Mucopurulent secretions are seen with both viral and bacterial infections. 
Secretions may be yellow or green, because thick, opaque, yellow secretions may be seen 
with uncomplicated viral nasopharyngitis.   
· Hyposmia or AnosmiaThis may occur secondary to nasal inflammation. 
· Facial or dental pressure or pain 
· Oropharyngeal Symptoms: Sore throat, Nasal obstruction may cause mouth 
breathing,  
· Halitosis 
· Cough: The cough may also be most prominent on awakening, occurring in 
response to the presence of secretions that have gathered in the posterior pharynx 
overnight.  
Daytime cough that lasts more than 10-14 days suggests sinus disease, asthma, or 
other conditions.  
Clinically significant amounts of purulent sputum may suggest bronchitis or 
pneumonia.  
· Fever: Fever may occur concomitantly with purulent nasal secretions in persons 
with sinus disease. Fatigue or malaise: These may be seen with any URI. 
· Mucosal edema and erythema: When rhinitis is present, nasal mucosa may be 
inflamed. Typical findings include swelling and redness of the turbinates. 
· Nasal obstruction due to preexisting polyps or septal deviation:  
· Suppuration: 
            Suspect an intracranial suppurative complication (eg, abscess) when the 
examination reveals signs such as proptosis, impaired extraocular movements, decreased 
vision, papilledema, changes in mental status. 
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RHINOPHARYNGITIS: 
Causes of Rhinopharyngitis: 
Adenovirus, 
Enterovirus 
Coxsackie virus, 
Parainfluenza virus. 
Symptoms of Rhinopharyngitis: 
· Pharyngeal symptoms include sore throat; Nasal obstruction may cause 
mouth breathing which may result in a dry mouth especially after sleep. 
· Cough : results from upper airway cough syndrome related to nasal 
secretions (post nasal drip) 
· Nasal symptoms include rhinorrhoea, congestion or obstruction of nasal 
breathing, sneezing. 
· Headache 
· Conjunctivitis is common with adenoviral and other viral infections. 
· Fever 
· Malaise or fatigue 
PHARYNGITIS:   
                 Acute pharyngitis is an inflammatory syndrome of the pharynx, usually caused 
by a virus but occasionally bacterial in origin. 
This is most often viral in origin. Importantly, group A streptococcal 
pharyngitis must be recognized because serious complications like scarlet fever, acute 
rheumatic fever and acute glomerulonephritis may follow untreated disease.  
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· Causes of viral Pharyngitis  
Adenovirus 
Influenza viruses 
coxsackievirus 
HSV, EBV (infectious mononucleosis) 
Cytomegalovirus  
· Causes of Bacterial pharyngitis: 
Group A streptococci (approximately 15% of all cases of pharyngitis), 
Group C and G streptococci 
Hemolyticum Corynebacterium diphtheria 
Atypical bacteria, such as M pneumoniae and C pneumoniae, anaerobic 
bacteria 
If symptoms persist beyond 10 days or progressively worse after the first 5-7 days, 
a bacterial illness is suggested. 
Symptoms of Pharyngitis: 
· Pharyngeal symptoms:  
Sore or scratchy throat,  
odynophagia, or dysphagia are common.  
If the uvula or posterior pharynx is inflamed, the patient may have an 
uncomfortable feeling of a lump when swallowing.  
· Secretions - These may be thick or yellow.  
· Cough: It may be due to laryngeal involvement or upper airway cough syndrome 
related to nasal secretions (postnasal drip). 
· Foul breath: This symptom may occur because resident flora process the products 
of the inflammatory process. 
· Headache: While common with group A streptococci and mycoplasma infections, 
it also may reflect URI from other causes. 
· Fatigue or malaise: These may occur with any URI. Extreme exhaustion is typical 
of influenza infection. 
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· Fever: While usually slight or absent, temperatures may reach 38.9°C (102°F) in 
infants and young children. 
· Rash: A rash may be seen with group A streptococcal infections, particularly in 
children or adolescents younger than 18 years. 
· Abdominal pain: This symptom may occur in streptococcal disease or with 
influenza and other viral conditions. 
EPIGLOTTITIS 
Inflammation of superior portion of larynx and supraglottic area 
Causes for Epiglottitis 
Group A streptococci,  
S pneumonia  
 M catarrhalis.  
This condition is more often found in children aged 1-5 years  
Symptoms of epiglottitis: 
Ø Sore throat 
Ø Drooling,  
Ø odynophagia or dysphagia,  
Ø difficulty or pain during swallowing,  
Ø globus sensation of a lump in the throat 
Ø Muffled dysphonia or loss of voice 
Ø Dry cough or no cough, dyspnea 
Ø Fever, fatigue or malaise (may be seen with any URI) 
LARYNGITIS: 
Laryngitis is swelling and irritation (inflammation) of the voice box (larynx) that 
is usually associated with hoarseness or loss of voice. Most of the causes of laryngitis, 
such as common viruses infections. 
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The voice box (larynx) is located at the top of the airway to the lungs (trachea). 
The larynx contains the vocal cords. When the vocal cords become inflamed or infected, 
they swell. This can cause hoarseness, and may sometimes block the airway. 
Causes for Laryngitis: 
· Allergies 
· Bacterial infection 
· Bronchitis 
· Gastroesophageal reflux disease (GERD) 
· Injury 
· Irritants and chemicals 
· Pneumonia 
· Occasionally, a person may develop laryngitis from bacterial infections, and 
rarely, from infections such as tuberculosis, syphilis, or a fungal infection. 
 
Symptoms of Laryngitis: 
· Fever 
· Hoarseness 
· Swollen lymph nodes or glands in the neck 
· Feeling a tickle in the throat (that may be from reflux laryngitis) 
· The urge to constantly clear the throat (that may be from reflux laryngitis) 
LARYNGOTRACHEITIS 
Inflammation of  larynx trachea  and subglottic area 
Causes of Laryngotracheitis: 
· This is typically caused by PIV type 1, 2, or 3. PIVs account for up to 80% of 
croup infections. PIV type 1 is the leading cause of croup in children. 
· Influenza viruses and RSV. 
· HMPV, 
· Adenovirus,  
· Rhinovirus, 
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· Enterovirus (including coxsackievirus and enteric cytopathic human orphan 
[ECHO] viruses) 
· Measles virus.  
 
SYMPTOMS: 
· Nasopharyngeal symptoms:  
Nasopharyngitis often precedes laryngitis and tracheitis by several days.  
Odynophagia or dysphagia may be reported.  
Swallowing may be difficult or painful.  
Patients may experience a globus sensation of a lump in the throat.  
· Hoarseness or loss of voice 
· Dry cough:   
Mild hemoptysis may be present.  
Barking cough, Whooping cough may be present. 
· Dyspnea and increased work of breathing:  
Symptoms may be worse at night because of changes in airway mechanics 
 while the patient is recumbent.  
· Myalgias are characteristic in influenza infection, especially in the setting of 
hoarseness with sudden sore throat, fever, chills, nonproductive cough, and 
headache. Fever may be present, but it is not typical in persons with croup. 
Fatigue or malaise may occur with any URI.  
TRACHEITIS: 
Tracheitis is a bacterial infection of the windpipe (trachea). 
Alternative Names: Bacterial tracheitis, Acute bacterial tracheitis 
Symptoms of Tracheitis: 
· Increasing deep or barking croup cough following a previous upper respiratory 
infection 
· Crowing sound when inhaling (in spiratory stridor) 
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· 'Scratchy' feeling in the throat 
· Chest pain 
· Fever 
· Ear ache 
· Trouble breathing 
· Headache 
· Dizziness (light headed) 
Complications: 
· Airway obstruction -- can lead to death 
· Toxic shock syndrome -- if caused by the bacteria Staphylococcus 
           COMPLICATIONS OF URTIs: 
Ø Pharynigitis/tonsillitis 
Ø Otitis Media 
Ø Sinusitis and/or peri-orbital cellulitis 
Ø Croup/laryngitis 
Ø Lower Respiratory Tract Infection (e.g. bronchiolitis or pneumonia) 
Ø Asthma or viral induced wheeze 
 SYMPTOMS AND SIGNS SUGGESTIVE OF SERIOUS ILLNESS: 
· High fever, fever > 72 hours, delayed onset of fever 
· Severe headache 
· Upper airway obstruction – stridor 
· Lower airway – dyspnoea, tachypnoea 
 SIGNS SUGGESTIVE OF COMPLICATIONS 
· Exudative tonsillitis 
· Tender anterior cervical lymphadenopathy 
· Otalgia, otorrhoea, hearing loss 
· Tenderness over sinus area 
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· Dyspnoea and Tachypnoea, pleuritic chest pain 
· Wheeze 
· Neck stiffness 
 
 DIAGNOSTIC TESTS FOR UPPER RESPIRATORY TRACT INFECTIONS 
Ø Complete blood count 
Ø Haemoglobin 
Ø Total count and differential count 
Ø Erythrocyte sedimentation rate 
Ø Absolute eosinophil count (AEC) 
Ø C-reactive protein levels 
Ø Radiograph of paranasal sinuses 
Ø Temperature 
Ø Gramstain for pathogens 
Ø IgE levels 
Ø Histamine levels 
OTHER RISK FACTORS FOR URTI: 
· Contact: Close contact with small children who frequent group settings, such as 
school or daycare, increases the risk of URI. 
· Travel: The incidence of contracting a URI is increased because of exposure to 
large numbers of individuals in closed settings. 
· Smoking and exposure to second-hand smoke: These may alter mucosal 
resistance to URI. 
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· Immunocompromise that affects cellular or humoral immunity: This 
increases the likelihood of contracting a URI.  
· Anatomic changes due to facial dysmorphisms,  
· Carrier state: Some people are chronic carriers of group A streptococci. Such 
individuals may have repeated URIs. 
 
DIET: 
· Fluid intake: Increased fluids are warranted to replace insensible losses and 
reduced oral intake. 
· Probiotics: Antibiotics alter the gastrointestinal flora, and some foods may not be 
as digestible for days or weeks after antibiotics are used. Consumption of yogurt 
containing active cultures has been advocated as an aid to restoring normal flora 
after antibiotic therapy.  
· Chicken soup increases the clearance of nasal mucous. 
· Drink lots of fluids (water, fruit juice, tea, clear soup broths and non-caffeinated 
carbonated beverages). 
Treatment 
· Anti tussive 
· Antibiotics 
· Anti-virals 
· Anti pyretic 
· De- congesant 
· Anti – histamine 
PREVENTION 
v  Wash the hands frequently, especially after touching public surfaces like 
doorknobs. 
v  Frequently wash toys, pacifiers, and other items that children tend to put in 
their mouths. 
v  Cover your mouth and nose when coughing or sneezing, and teach your 
children to do the same. 
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v        Limiting the child’s contact with people who may be sick, especially if 
your child is very young or especially at risk for getting sick. 
v  Special attention should be paid to these infection-control methods in 
situations where children are in large groups, such as preschools and day-
care centers. 
v Practicing good hygiene is very important. As the foods rich in simple 
sugars increases the osmotic load they should be avoided to children. 
v Rehydration therapy for the replenishment of water and electrolytes lost in 
stools should be given for children. 
v Intake of highly nutritious diet for increasing immunity and decreased 
suspectibility of infections in children. 
v Inhale warm moist air. Use a humidifier, take showers or put a pan of 
water on your radiator.  
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3.3 DRUG REVIEW 
 
SCIENTIFIC AND  SIDDHA PHILOSOPHICAL REVIEW OF TRAIL DRUG 
SATHAVERI KIRUDHAM 
1. த ண  வ டா  கிழ    -   (Asparagus racemosus) 
2. பர கிப ைட                        -   (Smilax china) 
3. ஏல கா                    -   (Elettaria cardmomum) 
4. ப வ  பா            -  (Cow’s milk) 
5. ெவ ளா    பா       -  (Goat milk) 
6. ÀÍ ¦¿ö                -  (Cow’s ghee) 
7. ேத கா   பா          -  (Coconut milk) 
1.  த ண வ டா  கிழ   (Asparagus racemosus) 
ENG.NAME                   :  Wild asparagus 
SANS                             :  Shataveri 
FAMILY NAME             :  Lilliaceae 
PART USED                  :  Leaf,tuberous roots 
SUVAI                           :  Sweet 
THANMAI                     :  Thatpam 
PIRIVU                          :  Sweet 
ACTIONS                      :  
                     உட ரமா கி 
                    உ ளழலா றி 
                பா ெப  கி 
   இசிவக றி 
 ண :  
ந ழிைவ  ேபா   ெந நா   ர ைதெயலா 
 ைரவ   ேதாட     கா -நா யேர 
ெவ ண  ெப  ேசாமேநா  ெவ ைட யன றண    
த ண  வ  டா கிழ   தா . 
                      -பதா  த ண வ ள க  
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ெவ   திர ,பைழய  ர ,ேசாமேராக ,ெவ ைள,உ    ஆகிய இைவகைள 
ந    எ க.       
Chemical consitutents:   Steroidal saponins (Shatavarins I-IV). 
                                                  Isoflavones, 
                                                  Asparagamine, 
                                                  Racemosol, 
                                                  Polysaccharides, 
                                                  Mucilage, 
                                                  Vitamins A, B1 , B2 , C, E, Mg, P, Ca, Fe, 
                                                   Folic acid 
Action: 
           Antitussive 
         Antibacterial activity 
 Antioxidant 
 Anti diuretic  
 Immunological Activity 
 antipyretic 
Reference: Indo-Global Journal of Pharmaceutical Sciences, 2011, Vol 1., Issue 2: Page 
No. 113-120  Phytomedicine-2002 
2.பர கிப ைட (Smilax china) 
ENG.NAME                   :  China root 
SANS                             :  Madusnuhi 
FAMILY NAME             :  Lilliaceae 
PART USED                  :  Rhizhome 
SUVAI                           :  Sweet 
THANMAI                     :  Thatpam 
PIRIVU                          :  Sweet 
 
ACTIONS                      :  
                    உட ேத றி 
                       ைமயா கி 
                ேமக ப ண  வ ல கி 
    காம ெப  கி  
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 ண : 
 தாக  பலவாத  தா ந ட    ப ளைவ 
 ேமக  க கிர தி வ   ல -ேதக ட  
   ைட பக தேம  ெகா வமன  ேபா பற கி  
 ப ைடய ைன  ச     பா . 
 - ேத.  
இதனா  ந ேவ ைக,ப பல வள ேநா ,  , ப ளைவ, ந ழி , க வ ட , சிர  , 
 ல ைள, டவாத , ைற ேநா , வா தி இைவ ந    
Chemical consitutents   :  S-Methyl cysteamine 
    Sulphoxid 
Action                             :  Anti-hyperuricemic 
                            Neproprotective 
                   Anti-oxident 
                  Anti-inflammatory 
Reference: J.ethanopharmacol 2011 may17; 135(2):399-405 
  Epub 2011 Mar 21 
  J.natural products 2010 73(9) 1489-1488 
3. ஏல கா  (Elettaria cardamomum) 
ENG.NAME                   :  Cardamom seeds 
SANS                             :  Ela 
FAMILY NAME             :  Zingiberaceae 
PART USED                  :  Seeds 
SUVAI                           :  Acrid 
THANMAI                     :  Veppam 
PIRIVU                          :  Acrid 
ACTIONS                      :  
                       ெவ ப  டா கி 
                      அக  வா வக றி 
                  பசீ த     
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 ண :  
  ெதா ைட வா க   தா   த கள  
               ேதா    ேநாயதி சார ப  ேமக தா   
         உ ைட ேபாெல   க   கி  சர  
   உழைல வா தி சில தி வ   ர  
         ப ைட ெவ ைக வ தாகேநா  காச   
   பா   ேசாம  ப ண வ    ந ட   
      அ ைட ய  ிைளவ  ப த  இைவ ெக லா  
                ஆல மா கம  ஏல ம  தேத…….. 
                                                -ேத.  
 ண :  
                இ  ெதா ைட,தா ,வா ,கீ வா  இைவகள  உ டா   
ேநா கைள  , இ ம ,கழி ச .ந      , ெந சி  ேகாைழ க  ,சில தி 
ந   இவ ைற   ேபா   :அழைல ஆ   , 
. Chemical consitutents: Alpha-Pinene, Sabinene, Myrecene, Limonene, Cineole, 
Cymene, Methyl Heptenone, Linalool, Linalyl acetate, Alpha and Beta Terpineol,  
Action:   Anti microbial activity 
                  Antipyretic activity 
                  Analgesic,  
     Anti-inflammatory,  
     Anti-Fungal,  
     Anti-Spasmodic,  
     Hepatoprotective. 
Reference:  International Journal of Research in Pharmacy and Chemistry, IJRPC 2011, 
1(4): 1152-1159 
4. ÀÍ ¦¿ö 
GENERAL CHARACTERS  
“¾¡¸ÓÆ ¨ÄÍðºõ Å¡ó¾¢ À¢ò¾õ Å¡ÔÀ¢Ã 
§Á¸õ ÅÂ¢ü¦ÈÃ¢× Å¢ì¸ÄÆø Á¡¸¡ºí 
ÌýÁõ ÅÈðº¢ Ì¼üÒÃð¼ ÄŠ¾¢Íð¸ï 
¦º¡ýÓÄõ §À¡ìÌ¿¢¨Èò ÐôÒ”  
«.Ì 
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ÀÍÅ¢ÉÐ ¦¿öÂ¡ÉÐ ¾¡¸õ,¯Æ¨ÄôÀ¢½¢,«¾¢Íð¸§Ã¡¸õ,Å¡ó¾¢, 
À¢ò¾¡¾¢ì¸õ,Å¡¾ Å¢„õ,Å¢Ã½ô À¢Ã§Á¸õ, ÅÂ¢üÈ¢¦ÄÃ¢×, À¢ò¾ Å¢ì¸ø, þÕÁø, 
ÅÂ¢üÚÅÄ¢,ÅÈðº¢,º¢¨ÉôÒ,Ì¼ø ¦¿Ç¢¾ø,«Š¾¢ ÝõÀø,ãÄ §Ã¡¸õ ¬¸¢ÂÅü¨È 
¿£ìÌõ.                                                       
GHEE (1 table spoon) – NUTRITION PROFILE 
Calories 112 kCal 
Water 0.03g 
Ash 0g 
Protein 0.04g 
Total lipid (fats) 12.73g 
Fatty Acids 
Saturated Fat 7.926g 
Polyunsaturated Fat 0.473g 
-Omega 6 (18:2) 0.288g 
-Omega 3 (18:3) 0.185g 
Amino Acids 
Tryptophan 0.001g 
Threonine 0.002g 
Isoleucine 0.002g 
Leucine 0.003g 
Lysine 0.003g 
Methionine 0.001g 
Phenylalanine 0.002g 
Tyrosine 0.002g 
Valine 0.002g 
Arginine 0.001g 
Histidine 0.001g 
Alanine 0.001g 
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Aspartic acid 0.003g 
Glutamic acid 0.008g 
Glycine 0.001 
Proline 0.003mg 
Serine 0.002g 
Vitamins 
Vitamin A 393IU 
- Retinol 105mcg 
-Retinol RAE 108mcg 
-Beta Carotene 25mcg 
Vitamin E (Alpha Tocopherol) 0.36mg 
Vitamin K 1.1mcg 
Riboflavin 0.001mg 
Pantothenic Acid 0.001mg 
Minerals 
Calcium, Ca 1mg 
Potassium, K 1mg 
Sterols 
Cholesterol 33mg 
 
 
5. ப வ  பா  (COW’S MILK) 
 ண :  
பால  கிழவ  ப   ர ேதா    ணாள  
 ைலய  ேமக ேதா    பல ேதா -ஏ மிவ   
எ லா    மா  மிைள தவ     சாதகமா  
ந லா  ப வ  பா  நா  . 
                                                                                      -ப.  
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 ண :  
ப வ  பால ன  பால    ,வ  த    , ராண  ர , ைல, 
ப ரேமக  ,   பல , அதி  கேராக  ஆகிய இைவகைள ைடயவ க     
ஆ   எ க. 
 
Chemical composition of Cow’s milk: 
Cow's milk (whole) 
Nutritional value per 100 g (3.5 oz) 
Energy 252 kJ (60 kcal) 
Carbohydrates 5.26 g 
Fat 3.25 g 
- saturated 1.865 g 
- monounsaturated 0.812 g 
- polyunsaturated 0.195 g 
Protein 3.22 g 
- Tryptophan 0.075 g 
- Threonine 0.143 g 
- Isoleucine 0.165 g 
- Leucine 0.265 g 
- Lysine 0.140 g 
- Methionine 0.075 g 
- Cystine 0.017 g 
- Phenylalanine 0.147 g 
- Tyrosine 0.152 g 
 56 
 
 
      
    
    
               
                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Valine 0.192 g 
- Arginine 0.075 g 
- Histidine 0.075 g 
- Alanine 0.103 g 
- Aspartic acid 0.237 g 
- Glutamic acid 0.648 g 
- Glycine 0.075 g 
- Proline 0.342 g 
- Serine 0.107 g 
Water 88.32 g 
Vitamin A equiv. 28 μg (4%) 
Thiamine (vit. B1)  0.044 mg (4%) 
Riboflavin (vit. B2)  0.183 mg (15%) 
Vitamin B12  0.44 μg (18%) 
Vitamin D  40 IU (7%) 
Calcium 113 mg (11%) 
Magnesium 10 mg (3%) 
Potassium 143 mg (3%) 
Sodium 43 mg (3%) 
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6. ெவ ளா    பா  (GOAT MILK) 
 ண :  
ெவ ளா    பா    ேமவ யந  ற  பனமா  
த ளா  வாதப த  சா தமா -உ ள ைர    
சீதமதி சார  சிேல மம     ணா   
வாதகி ேலச  ேபா மா   . 
 ண : 
 ெவ ளா    பாலினா  வாதப த ெதா த , வாசேராக ,சீத கல த 
ேபதி.கபேதா  .வ ரண ,வாத தா  டாகிய வ  க  தலிய  ப க  
ந   .ந ல பசி  டா   எ க,. 
 
Chemical Composition Of Goat Milk: 
 
Constituents Unit Goat 
Water G 88.9 
Protein G 3.1 
Fat G 3.5 
Saturated fatty acids G 2.3 
Monounsaturated fatty acids G 0.8 
-Polyunsaturated fatty acids G 0.1 
Carbohydrate (Sugars i.e Lactose) G 4.4 
Energy in Calories kcal 60 
Energy in Joules kJ 253 
Cholesterol mg 10 
Calcium mg 100 
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7.  ேத கா   பா ( Coconut milk) 
ENG.NAME                   :  Coconut palm 
SANS                             :  Narikela 
FAMILY NAME             :  poaceae 
PART USED                  :  All parts 
SUVAI                           :  Sweet 
THANMAI                     :  Thatpam 
PIRIVU                          :  Sweet 
ACTIONS                      :  
                       சி ந  ெப  கி 
                      உட ரமா கி 
                மலமிள கி 
                                   ள   சி  டா கி 
 ண : 
வாதமா  ப த    வ கர ப  பட   
தா    வ  தியா  தா  ழேல-ேயாதந ல 
அ ன மிற   மதி  ைச  டா   
ெத ன கா   பாலா  ெறள , 
Chemical composition of Coconut milk: 
Coconut milk, canned 
Nutritional value per serving 
Serving size 100 g 
Energy 824 kJ (197 kcal) 
Carbohydrates 2.81 g 
Fat 21.33 g 
- saturated 18.915 g 
- monounsaturated 0.907 g 
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- polyunsaturated 0.233 g 
Protein 2.02 g 
Water 72.88 g 
Vitamin C 1 mg (1%) 
Calcium 18 mg (2%) 
Iron 3.30 mg (25%) 
Magnesium 46 mg (13%) 
Phosphorus 96 mg (14%) 
Potassium 220 mg (5%) 
Sodium 13 mg (1%) 
Zinc 0.56 mg (6%) 
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4. MATERIALS AND METHODS 
4.1 PREPARATION OF SATHAVERI KIRUDHAM (SVK) 
Vali kanam is one of the frequently encountered problem among young children 
in India. Hence it was proposed to study about the disease. A Protocol was prepared  and 
submitted before IEC & IAEC of National Institute of Siddha. After obtaining approval 
from the commitee, the study Preclinical study & clinical study on Vali Kanam (URTI) in 
children and the drug of choice was Sathaveri Kirudham was carried out as per the 
protocol. 
The ingredients for preparation of experimental formulation Sathaveri Kirudham 
was purchased from a well reputed country shop and raw drugs were authenticated by 
Herbal botanist. The medicine was prepared in Gunapadam lab of National institute of 
Siddha after proper purification.The prepared medicine was  also authenticated by the 
concerned Head Of The Dept for its completeness.   
Ingredients:   
1. Thaneervittan kizhangu  (Aspragous Racemosus Linn ) 
2. Parangi chakkai chooranam (Smilax China Linn) 
3. Aelarisi chooranam (Elettaria Cardamomum Linn) 
4. Coconut milk (Cocous Nucifera Linn) 
5. Cow’s milk 
6. Cow’s ghee 
7. Goat milk 
8. Karkandu chooranam (Sugar candy). 
Ø Prepration- All the raw drugs would be powdered and make it as 
chooranam.Coconut milk,Cow’milk,Goat milk and Cow’s ghee would be  
put into the used mudpot and  boiled until it will be formed as a waxy .Then 
the medicated ghee would be filtered and then sugar candy added.  
Ø Purification: All raw drugs will be purified as per Siddha principle 
Ø Indication: All types of Kanam 
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INGREDIENTS OF SATHAVERI KIRUDHAM 
ASPARAGUS RACEMOSUS                     ASPARAGUS RACEMOSUS(Dried) 
 
                            
 
                       SMILAX CHINA                                                     COW MILK 
 
                           
 
 
 
 
 
 
 
ELETTARIA CARDAMOMUM                                                  GOAT MILK 
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COCONUT    MILK                                                       GHEE 
                                                                          
      KALKANDU      SATHAVERI KIRUDHAM                            
                                                                                                                             
 
 
                 
                              
 
 
Even though the drugs were pure herb, safety of Sathaveri kirudham  by  Acute and Sub 
acute Toxicity studies were done  in animal models according as per  WHO guidelines, 
1993. For acute toxicity mice and for subacute toxicity study rat were used. 
4.2 PRECLINICAL STUDIES 
4.2.1 Inductively Coupled Plasma Optical Emission Spectrometry   
The elemental composition of a sample is often an important part of the 
information needed to assess its properties.  Hence there is a need for sensitive scientific 
instrumentation like ICP-OES which plays a pivotal role in the determination of these 
elements. ICP-OES is widely employed for the estimation of metals and metalloids at 
trace, minor and major concentrations.  
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Principle    
In this technique, the high temperature plasma source atomizes the sample and 
excites the atoms resulting in emission of photons .The atoms of each element in the 
sample emit specific wavelength of light. The emission spectrum from the plasma is 
dispersed by an optical spectrometer, so that intensities of the individual wavelength can 
be measured. The number of photons emitted is directly proportional to the concentration 
of the element. The photon may be detected either sequentially or simultaneously. 
Quantitative analysis is achieved by measuring the intensity of these specific wavelengths 
and after performing the calibration using known standards. 
Formation of the Plasma 
Plasma is a cloud of electrons and ions held at high temperature. Figure 1 shows 
the cross section of an ICP torch and load coil depicting an ignition sequence.  
          A) Argon gas is swirled through the torch; B) RF frequency   is applied to load 
          Coil C) A spark produces some free electrons in the argon D) The free electrons 
          are accelerated by the RF fields causing further ionization and forming a  plasma & 
          E) The sample aerosol – carrying nebulizer flow punches a hole in the plasma. 
Adding energy to the electrons by the use of a coil in this manner is known as 
inductive coupling. Figure 2 shows the Zones of the ICP. There are four important zones 
in the plasma namely, induction region, preheating zone, initial Radiation zone and 
normal analytical zone. 
The first function of the high temperature plasma is to remove the solvent from, or 
desolvate, the aerosol, usually leaving the sample as microscopic salt particles.  The next 
steps involve decomposing the salt particles into a gas of individual molecules 
(vaporization) that are then dissociated into atoms (atomization). These processes, which 
occur predominantly in the preheating zone (PHZ).     
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Once the sample aerosol has been desolvated, vaporized and atomized, the plasma 
has one, or possibly two, functions remaining.  These functions are excitation and 
ionization.  In order for and atom or ion to emit characteristic radiation, one of its 
electrons must be promoted to a higher energy level through an excitation process.   Since 
many elements have their strongest emission lines emitted from the ICP by excited ions, 
the ionization process may also be necessary for some elements.  The excitation and 
ionization processes occur predominantly in the initial radiation zone (IRZ) and the 
normal analytical zone (NAZ). The NAZ is the region of the plasma from which analyte 
emission is typically measured.   
Extraction of information 
Obtaining qualitative information, i.e., what elements are present in the sample, 
involves identifying the presence of emission at the wavelengths characteristic of the 
elements of interest.  Obtaining quantitative information, i.e., how much of an element is 
in the sample, can be accomplished using plots of emission intensity versus concentration 
called calibration curves.  
ICP-OES System available at SAIF, IITM 
The PE Optima 5300 DV ICP-OES instrument  at SAIF is  a Dual View (DV) 
instrument in which the the plasma can be viewed either axially or radially. It has got a 
dual detector system.  The UV detector covers an extended ultraviolet wavelength from 
165 to 403 nm.  The VIS detector covers the visible wavelength range from 404 to 782 
nm.    
The torch is positioned horizontally in the sample compartment along the central 
axis of the spectrometer optics. Changing from axial to radial viewing is a simple 
software Command and is accomplished by computer control of a mirror located in the 
optical path. 
The torch assembly of this system comprises of two concentric quartz tubes with a 
standard alumina injector with a 2.0 mm inner diameter. The spray chamber is of Scott 
type and the nebulizer is a cross flow Gem tip.  
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How the Echelle Spectrometer and SCD Work 
The echelle grating is a coarse grating with a ruling density of 79 lines/mm.  It is 
precisely ruled with broad flat grooves.  The width of each groove is twice the height. 
Because of this groove shape, this grating is often compared to a series of steps, with 
diffraction occurring off the steep side of the steps.  This produces multiple, overlapping 
diffraction orders with very good efficiency in each of the orders.  The echelle grating is 
optimized through the blaze angle to have a maximum efficiency in one of its lower 
orders. An echelle grating is that it has high dispersion characteristics since it is used in 
the higher diffraction orders. 
UV Module 
The UV module consists of a cross disperser, a camera sphere, a fold flat mirror, a 
field flattener, and the detector module. 
Schmidt Cross Disperser 
The Schmidt Cross Disperser serves three purposes in the optical system.  First, 
the Schmidt cross disperser separates the light into the visible and UV channels.  Light 
reflecting off the surface of the Schmidt Cross Disperser is sent to the UV detector. Light 
passing through the opening in the center of the optic becomes the visible channel.  
Second, the front surface of the Schmidt Cross Disperser is a coarse grating with a ruling 
density of 374 lines / mm.  This separates or “cross disperses” the overlapping orders into 
the 2D echelle pattern or echellogram. By using a grating instead of a prism for the cross 
disperser, optical throughput in the UV is enhanced. Third, the surface of the Schmidt 
Cross Disperser has a small waveform on it.  This waveform corrects for the spherical 
aberrations generated by the camera sphere mirror. By correcting for these spherical 
aberrations, the UV channel has excellent optical throughput (f/2.5) and excellent 
resolution (0.006nm at 200nm).   
Dual Density Cross Disperser 
This is a grating that is ruled with two different line densities.  A computer 
controlled mechanism allows selection of either the UV or VIS region of the grating.  In 
addition, Schmidt correction is incorporated into the surface of the grating to eliminate 
spherical aberration of the camera sphere. 
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Fold Flat Mirror 
 The fold flat mirror deflects the UV light onto the detector.  The fold flat mirror 
size matches the size of the opening in the Schmidt Cross Disperser.  Thus, the mirror 
does not impact the optical throughput of the system.  The field flattener is a lens that 
provides good focus for the entire Wavelength range on the UV detector. 
Visible Module 
 The overlapping orders from the echelle grating are passed through the opening in 
the Schmidt Cross Disperser to the visible prism.  This prism separates the overlapping 
orders into discrete orders. A two-dimensional pattern or echellogram is produced. A 
compound lens directs the beam onto the solid-state detector for the visible range. 
Segmented-array Charge-coupled-device Detector (SCD) 
The detector is a silicon chip with a surface area of 13 mm by 19 mm.  On its 
surface, the chip has a series of linear subarrays comprised of pixels.  The pixels are 
photosensitive areas of silicon that have an aspect ratio of approximately eight to one. 
This aspect ratio matches the slit geometry of the instrument and ensures excellent optical 
throughput. Also, unlike other charge-transfer device detectors, the pixels have no UV-
absorbing polysilicon electrodes over the detector surface.  Thus the quantum efficiency 
of the SCD is very good throughout the entire wavelength range of the instrument. The 
linear subarrays are positioned on the detector at x-y locations that correspond to the 
locations of the desired emission lines generated by the echelle spectrometer. 
The Fig.7 Shows a representation of the echelle pattern on the detector.  The 
diffraction orders are positioned along the x-axis and the emission lines are positioned 
along the y-axis. The emission lines are detected by means of their location on the chip. 
Each linear subarray contains from 8 to 40 pixels.  Each pixel is 25 µm wide and 
approximately 100 µm in height.  The height of the pixels varies based on its position on 
the detector and the width of the echelle order at that position.  The emission line for the 
analyte of interest falls on the subarray along with the spectral information on each side 
of the peak. Thus the analyte peak and the spectral background are measured 
simultaneously. 
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Electronic processing of the Signal 
On the Optima 5300 the detector consists of 235 subarrays. The number of 
subarrays that are used depends on the wavelength range of the instrument.  The subarray 
(Figure 8) consists of three areas, the photosensitive area, the storage register and the 
output register.  
Surrounding this sub array is a “guard band” that prevents excessive charge from 
blooming onto any other subarray.  Next to each subarray are the output electronics and 
the interface logic.  Since the output electronics are next to the output register, the 
capacitance is extremely small and thus the readout noise is very low ( app 13 electrons 
RMS).  Since each subarray has its own interface logic, it can be addressed and read out 
individually. All the address lines, output electronics, and interface logic are covered by 
an opaque mask to block unwanted radiation. 
The cross section of the detector. 
 Photons strike the photosensitive register and are immediately converted to 
photoelectrons.  These photoelectrons are pulled away from the surface and moved into 
the storage register where they are stored as an electrical charge. The integration time is 
the length of time that these photoelectrons are allowed to accumulate in the storage 
register.  When the integration is complete, the charge in the storage register is transferred 
into the output register by a change in the electrical potential. The charge in the output 
register is serially moved to the output electronics where it is amplified and sent to the 
signal processing electronics. 
Applications 
· Silicate rock analysis 
· Analysis of geo-chemical samples 
· Water analysis 
· Analysis of environmental samples 
· Analysis of archaeological samples 
· Analysis of biological samples like blood serum, cerebrospinal fluid and urine 
· Analysis of polymer samples and refractory compounds. 
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4.2.2  ACUTE TOXICITY STUDY [WHO guidelines, 1993] 
Acute toxicity was carried out in Swiss albino mice with a single exposure of 10 
times of the recommended therapeutic dose of test compound the study duration will be 
14 days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 10 
Acclimatization Period : 14 Days 
Clinical dose   : 10ml / day 
 
S.No Group No of mice 
1 Vehicle control (saline) 10  (5 male, 5 female) 
 
2 
Toxic dose 
10X therapeutic dose 
(1.26ml) 
10  (5 male, 5 female) 
Test Animals  
      Test animals were obtained from the animal laboratory of the King institute, 
Chennai and stocked at National institute of siddha, Chennai. All the animals were kept 
under standard environmental condition (27+ or – 2 degree c).The animals had free access 
to water and standard pellet diet (Sai Durga foods pvt.ltd, Bangalore).The principles of 
laboratory animal care were followed and the  Institutional ethical committee approved 
the use of animals and the study design. (1248/ac/09/CPCSEA/February/ 2012) 
 Route of administration: 
 Oral route was selected, because it is the normal route of clinical administration. 
Test substance and vehicle 
       Sathaveri kirudham is dark brown in colour.  The test substance is insoluble in 
water, in order to obtain and ensure the uniformity in drug distribution the drug is 
dissolved by aqueous Tween 80 solution (30%).  
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Administration of doses 
           Sathaveri kirudham  was suspended in aqueous Tween 80 solution (30%), with 
uniform mixing and it was administered to the groups in a single oral dose .The control 
groups were received equal volume of the vehicle. The animals were weighed before 
giving the drug. The dose level was calculated according to body weight, and surface 
area. Since the clinical dose was 10ml\day it was converted to animal dose (1.26ml) and 
then administered. The principle of laboratory animal care was followed. 
Observations 
 Observations were made and recorded systematically and continuously observed 
as per the guideline after substance administration. The animals were monitored for 
behavioural parameters like 
1. Awareness 
- Alertness 
- Visual placing 
- Stereotype 
- Passivity 
2. Mood 
-  Grooming 
-  Restlessness 
-  Irritability 
-  Fearfulness 
 
3. Motor activity 
- Spontaneous activity 
- Reactivity 
- Touch response 
- Pain response.  
Animals were observed for body weight and mortality for 14 days. If animals died 
during the period of study, the animals were sacrificed.  At the end of the 14th day all 
animals were sacrificed and necropsy was done. 
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Body Weight 
 Individual weight of animals was determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the 
end of the test, surving animals were weighed and sacrificed. 
4.3 CLINICAL STUDIES 
After finishing the toxicity studies 40 cases were selected from the OPD & IPD of 
Kuzhandhai Maruthuvam Department, National Institute of Siddha. They were treated 
with the trial drug Sathaveri kirudham and observed for prognosis clinically. 
STUDY DESIGN & CONDUCT OF STUDY. 
    Study type :     An open clinical study 
  Study place :   OPD. & IPD. Of Ayothidass pandithar hospital, 
                                    National Institute of Siddha ,  
                    Tambaram sanatorium, Chennai-47. 
  Study duration : 12 Months 
  Treatment period :  20 days 
Population and sample: 
· Population consists of pediatric patients attending the OPD of Ayothidoss 
Pandithar Hospital, National Institute of Siddha, Chennai-47. 
· The sample consists of patients 3-12 years age group fulfilling all the inclusion 
criteria and exclusion criteria. 
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PATIENT SCREENING 
 
INCLUSION CRITERIA 
EXCLUSION CRITERIA 
 EXCLUDED FROM TRIAL 
METHODOLOGY 
LAB INVESTIGATION 
 TRIAL DRUG  
GIVE GENERAL TREATMENT 
CLINICAL ASSESSMENT 
OUTCOME 
     HISTORY TAKING 
       STUDY NUMBER 
INFORM ABOUT STUDY AND 
TRIAL DRUG 
 INFORMED COSENT FORM 
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INCLUSION CRITERIA             
Ø Patient who complained with symptoms of Vali kanam.Like 
Cough, Irritant sensation in throat, Rumbling noise in stomach, 
Excessive thirst, Fever ,Lack of appetite, Dysuria 
Ø Age: 3-12 years of both sex 
Ø Parent/guardian of the Patient willing to sign the informed 
consent.  
Ø Patients who are willing to accept radiological investigation 
and provide blood sample for lab investigation when required. 
 
EXCLUSION CRITERIA 
Ø Active primary complex 
Ø Jaundice,  
Ø enteric fever or long term fever,  
Ø pneumonia 
Ø congenital heart diseases 
Ø  Severe asthma 
Ø Any other serious illness 
 
 Sample size   40 patients 
TREATMENT MEDICINE NAME:  
                               Sathaveri Kirudham 
 Dosages* 
· 3-5 yrs           -6 ml       
· 6-8 yrs          -7 ml                                
· 9-12 yrs         -9 ml 
* Dose calculation for pediatric group is based on Height and Weight chart, ICMR, 1990; 
and the formula mentioned in the Essential of medical pharmacology by K.D. Tripathi    
Duration:  20 days 
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 STUDY ENROLLMENT 
   Patients reporting at the OPD with the clinical symptoms of  Cough, Irritant 
sensation in throat, Thirst, Fever, Rumbling noise in stomach, Lack of appetite, Dysuria 
will  be examined clinically for enrolling in this study based on the inclusion and 
exclusion criteria.  
· The patients who were  enrolled and their parents were  informed about the study, 
trial drug, possible outcomes and the objectives of the study in the language and 
terms understandable to them. 
· After ascertaining the patients’ willingness, informed consent (Form II ) was 
obtained in writing from their parents in the consent form. 
· Complete clinical history, complaints and duration, examination findings were  
recorded in the prescribed Proforma in the history and clinical assessment forms 
separately. Screening Form- I was be filled up. Form III,   Form –IV and Form –V 
were used for recording the patient’s history, clinical      examination of symptoms 
and signs and laboratory investigations respectively. 
· Patient were  advised to take the trial drug and appropriate dietary advice  was 
given according to the patients’ perfect understanding 
CONDUCT OF THE STUDY: 
            In the OPD, after initial tests and assessment The trial drug “Sathaveri Kirudham 
is given continuously for 20 days. For OP patients, they were visit the hospital once in 7 
days.  At each clinical visit clinical assessment is done and prognosis was noted.   For IP 
patients the drug is provided daily and prognosis is noted and also clinical assessment was 
done .Laboratory investigations & radiological investigation are done 0 day & 20 th day 
of the trial. For IP patients, who is not in a situation to stay in the hospital for a long time 
is advised to attend the OPD for further follow-up. After the end of the treatment, the 
patients were  advised to visit the OPD for another 2 months for follow-up. 
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DATA MANAGEMENT 
· After enrolling the patient in the study, a separate file for each patient was 
opened and all forms were filed in the file. The Data recordings were monitored 
for completion and adverse event. 
The following ASSESSMENT FORMS were used for data collection: 
FORM I  SCREENING & SELECTION PROFORMA 
 FORM II  CONSENT FORM 
FORM III  HISTORY PROFORMA  
 FORM IV  CLINICAL ASSESSMENT FORM 
FORM V  LABORATORY INVESTIGATION FORM 
FORM VI  PATIENT’S INFORMATION SHEET  
FORM VII  WITHDRAWAL FORM 
FORM VIII  ADVERSE REACTION  FORM 
FORM IX  DIETARY ADVICE FORM  
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5. RESULTS AND OBSERVATIONS 
5.1 PRECLINICAL STUDIES  
5.1.1  Inductively Coupled Plasma Optical Emission Spectrometry of SVK 
ICP-OES is widely employed for the estimation of metals and metalloids at trace, 
minor and major concentrations. Sathaveri Girutham has been analysed for the ion 
concentration with ICP-OES. The following result shows concentration ion present in the 
experimental formulation. 
Analyte                       Mean 
§ As193.696   BDL 
§ Ca 317.933    154.695 mg/L 
§ Cd 226.502                         BDL 
§ Cu 324.754   BDL 
§ Fe 238.204   35.248  mg/L 
§ Hg253.652                         BDL  
§ K 766.491    58.249 mg/L 
§ Mg 257.610    8.295 mg/L 
§ Na 588.995    55.996 mg/L 
§ P 214.914     24.215 mg/L 
§ Pb 230.204                       BDL 
§ S 181.975    7.287 mg/L 
§ Se 196.090      4.199 mg/L 
§ Zn 213.856   13.752 mg/L 
 
BDL=Below  detection limit 
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5.1.2  ACUTE TOXICITY STUDY OF SVK 
  Sathaveri kirudham at the dose 1.26ml/animal did not exhibit any mortality in 
mice. No behavior changes were noted for the first 4 hours and for the next 24 hours and 
throughout the study period of 14 days. No weight reduction was noted before and after 
the acute study duration. Reflexes were found to be normal before and after the study. All 
other observations were found to be normal before and after the study. In Necropsy, the 
organs of the animal such as, Liver, Heart, Lungs, Pancreas, Spleen, Stomach, Intestine, 
Kidney, Urinary bladder, Uterus all appeared normal. 
5.2 CLINICAL STUDIES 
40 Patients with confirmed diagnosis of Valikanam with satisfying the inclusion 
criteria were enrolled after obtaining written informed consent and were to receive 
SATHAVERI KIRUDHAM with dosage of 6-10 ml BID for 20 days. 
Results were observed with respect to the following criteria: 
1. Age 
2. Sex 
3. Parent’s Socio Economic Status 
4. Diet 
5. Paruvakaalam 
6. Uyir thathukkal 
7. Ezhu udal kattugal 
8. Envagaithervugal 
9. Neikuri 
10. Cllinical features 
11. Haemotological Profile 
12. Biochemical Analysis 
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Table 1 
Distributions of patients with valikanam according to Age Distribution 
Age No of cases Percentage 
 3-5 years 17               42.5 
6-8 years 13 32.5 
9-12 years 10 25 
Chart -1 
 
 
Inference: 
 Out of 40 patients, 42.5% of cases were 3-5 years, 32.5% were 6-8 years, 25% 
were 9-12 years. 
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Table 2 
 
Distributions of patients with Valikanam according to  
Gender Distribution 
 
Gender No of cases Percentage 
Male child 20 50 
Female child 20 50 
Total 40 100 
 
Chart -2 
 
 
Inference: 
Out of 40 patients 50% were male children and 50% were female children.    
So there is no marked difference in sex distribution and this disease can affect either sex. 
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Table 3 
Distributions of patients with valikanam according to 
 parent’s Socio Economic Status 
  Socio Economic Status      No of  Patients            Percentage(%) 
Lower Income Groups                    15                 37.5 
 Middle Income Group                    20                 50 
 High Income Groups                     5                12.5 
Total                     40                100 
             Chart -3 
 
Inference:  
 About 37.5% patients were under Lower Income Group, 50% patients were under 
Middle Income Group and 12.5% patients were under High Income Group.  The highest 
incidence occurred in middle Income Group. 
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Table 4 
Distributions of patients with valikanam according to Diet 
Diet No of Cases Percentage 
Vegetarian 4 10 
Mixed 36 90 
Total 40 100 
             Chart -4 
 
 
Inference:  
 According to diet, high incidence of cases (90%) was noted in mixed and in 
vegetarian 10% cases were noted. 
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Table 5 
Distributions of patients with valikanam according to Paruva Kalam  
(Seasonal Variation) 
Paruva kalam No. of Cases Percentage 
Karkalam 8 20 
Koothirkalam 25 62.5 
Munpani kalam 7 17.5 
Pinpanikalam 0 0 
Elavenil kalam 0 0 
Muthuvenil kalam 0 0 
Total  40 100 
            Chart -5 
 
Inference: 
According to paruva kaalam, high incidence of cases (62.5%) were noted in 
Koothirkaalam. In karkalam 20%cases were noted, In munpani kalam 17.5% cases were 
noted.  
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Table 6a. 
Distributions of patients with valikanam according to Vali (Vatham) 
Types of vatham No of Cases Percentage (%) 
Pranan 40 100 
Abanan 16 40 
Viyanan 0 0 
Uthanan 40 100 
Samanan 40 100 
Naagan 0 0 
Koormam 0 0 
Kirukaran 40 100 
Devathathan 15 37.5 
Dhananjeyan - - 
             Chart – 6a 
 
 
Inference: 
 `According to vadham, derangement of Pranan, Uthanan, Kirukaran and Samanan 
was 100%, Abanan was deranged in 40%, Devathathan was deranged in 37.5%. 
 
0
10
20
30
40
50
60
70
80
90
100
40
16
0
40 40
0 0
40
19
0
100
37.5
0
100 100
0 0
100
37.5
0
Vadham
NO OF CASES
PERCENTAGE 
 83 
 
Table 6.b 
Distributions of patients with Valikanam according to Azhal (Pitham) 
Types Of Azhal No. of Patients Percentage (%) 
Analagam (Aakanal)  40 100 
Ranjagam (Vannaerri) 23 57.5 
Sathagam (Aatralangi ) 40 100 
Alosagam (Nokkanal) - - 
Prasagam (Oollolithee) 23 57.5 
            
  Chart -6b 
 
 
Inference:  
According to Pitham, derangement of Analagam, Sathagam was deranged in 
100%, Ranjekam, Prasagam was deranged in 57.5% . 
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Table 6.c 
Distributions of patients with Valikanam according to Iyam (kabam) 
Types of  Iyyam No. of Patients Percentage (%) 
Avalambagam (Alliyyam)                 40                 100 
Klethagam (Neerpiyyam)                 40                   100 
Pothagam (Suvaikanaiyyam) - - 
Tharpagam (Niraivaiyyam) - - 
Santhigam (Oondriyyam) - - 
              
Chart -6c 
 
 
 
Inference:  
 `According to Kabam, derangement of Avalambagam was 100%, Kelathagam was 
deranged in 100% . 
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Table  7. 
Distributions of patients with valikanam according to Ezhu udal thaathukkal 
Udal thaathukkal No of Patients Percentage (%) 
Saaram   40 100 
Senneer  22 55 
Oon  0 0 
Kozhuppu 0 0 
Enbu    0 0 
Moolai      0 0 
Sukkilam 0 0 
Suronitham 0 0 
             
 Chart -7 
 
 
 
Inference:  
Saram was affected in 100% of cases, Senneer was affected in 55% of cases . 
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Table - 8 
Distributions of patients with valikanam according to Envagai thervugal 
Ennvagai thervukal No of cases Percentage 
Naadi: Vathapitham                    
 Pithavatham
 Pithakabam 
34 
4 
2 
85 
10 
5 
Sparisam 20 50 
Naa 23 57.5 
Niram 20 50 
Mozhi 8 20 
Vizhi 23 57.5 
Malam - - 
Moothiram 16 40 
 
             Chart -8 
 
 
Inference: 
In Naadi, Vathapitham was observed in 85% of cases, Pithavatham was observed 
in 10% of cases, Pithakabam was observed in 5% of cases.   
Out of 40 cases coated and slightly dried tongues were noted in 57.5% cases.  
In Niram, pallor of skin was observed in 50% of cases. 57.5% of cases were found 
pallor conjunctiva. Out of 40 cases, low grade fever was observed in all 50% of cases. 
According to Moothiram, enjal was observed in 40% of cases. 
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Table - 09 
Distributions of patients with valikanam according to Neikuri 
Neikuri No. of Patients Percentage (%) 
Vaatham 23 57.5 
Pitham 9 22.5 
Kabam 8 20 
              
Chart -9 
 
 
Inference 
According to Neikuri, Vatha neer was observed in 57.5% of cases, pitha neer was 
observed in 22.5% of cases, Kaba neer was observed in 20% of cases. 
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Table - 10 
Distributions of patients with valikanam according to the clinical features 
Clinical 
Features 
No of patients 
observed  
Before 
treatment 
Percentage 
(%) 
No of patients 
observed 
after treatment 
Percentage 
(%) 
Rumbling noise in 
stomach 19 47.5 5 12.5 
Throat irritation 40 100 7 17.5 
Cough 40 100 11 27.5 
Excessive thirst 20 50 3 7.5 
Fever 20 50 0 0 
lack of Appetite 40 100 10 25 
Dysuria 16 40 2 5 
 
             Chart -10 
 
Inference 
Among the 40 cases, 100% of the patients had throat irritation, cough, lack of 
appetite. Rumbling noise in stomach had 47.5%, 40% of patients had dysuria, 50% of 
patients had excessive thrist and fever in 50% of cases at the base the treatment. At the 
end of the treatment, throat irritation in 17.5% of cases, rumbling noise in stomach in 
12.5% of cases, cough in 27.5% of cases, dysuria in 5% of cases, excessive thrist in 7.5% 
of cases, lack of appetite in 25% of cases were noted.  
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12.  Laboratory investigations 
Most of cases were had increased WBC and AEC, reduced hemoglobin level. 
Sputum for AFB negative for all cases. 
13. Biochemical analysis 
The Bio chemical analysis of trial medicine showed the presence of Calcium and 
Ferrous Iron, Starch, Tannin, Phosphate, Alkaloids.  
Table - 11 
Result 
Result No. of Patients Percentage (%) 
Good Relief 25 62.5 
Moderate Relief 10 25 
Mild Relief 5 12.5 
Total 40 100 
             Chart -11 
 
Inference: 
Out of the 40 cases, the signs and symptoms were good in 62.5% of cases, 
moderate in 25% of cases, mild in 12.5%. These results were based on the clinical 
improvements. 
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                                                                                      LAB INVESTIGATION 
S. 
NO 
OP/IP 
No 
Age/ 
sex 
(Haematology) BEFORE TREATMENT (Haematology) AFTER TREATMENT  
Total 
WBC 
Cells/ 
cu.mm 
DIFFERENTIAL COUNT 
ESR 
(mm) 
Hb 
Gm
% 
TRB
C 
cells / 
cu.m
m 
AEC 
Total 
WBC 
cells/ 
cu.mm 
DIFFRENTIAL COUNT ESR (mm) HB 
Gm
% 
TRBC 
cells / 
cu.mm 
AEC 
P% L% E% M 1/2hr 1 hr P L E M 1/2hr 1 hr 
1. B37489 12/Fch 8.600 63% 33% 04% 0 2 4 10.6 4.3 358 8400 55 41 4 0 2 4 11.2 3.9 290 
2. C.94670 9/fch 10,000 47% 44% 09% 0         2 6 14.1 5.6 430 9900 50 45 4 1 3 6 13.5 5.4 275 
3. C.91069 12/fch 6.400 46% 49% 05% 0 2 6 13.2 5.1 411 7000 46 51 3 0 2 6 13.0 4.8 148 
4. B.34232 9/mch 6.600 40% 55% 05% 0 2 6 10.4 4.2 440 6400 55 41 4 0 2 6 11.4 4.5 400 
5. C.81856 11/fch 6.500 30% 61% 09% 0 6 12 14.2 4.9 378 6000 45 50 3 2 3 6 14.0 5.0 350 
6. C.098213 10/fch 6.000 30% 55% 15% 0 2 4 12.1 4.5 341 6400 44 50 6 0 4 8 13.0 4.7 375 
7. C.91219 12/fch 8000 45 50 5 0 4 8 11.2 4.0 275 7800 55 43 2 0 2 4 12.0 4.2 250 
8. C3728 5/mch 11800 68 19 13 0 4 10 14.4 5.1 666 9900 54 43 3 0 2 8 13.4 4.6 440 
9. C.98678 7/fch 7.600 41% 54% 05% 0 4 8 12.1 4.0 413 7800 45 53 2 0 2 6 11.2 4.5 354 
10. D010915 7/mch 10.000 47% 38% 04% 0 2 8 11.2 4.7 386 9800 54 43 3 0 3 6 11.6 4.7 300 
11. C.59018 8/mch 8,700 32% 60% 08% 0 2 6 14.5 5.1 456 9000 40 55 4 1 10 20 13.6 4.5 250 
12. C.93356 6/mch 9.900 54% 40% 06% 0 12 14 14.4 5.0 331 9900 54 40 06 0 12 26 14.4 5.0 88 
13. C.61680 7/Mch 12000 27% L51
% 
21% 0    6   16 13.5 5.1 1755 10500 30 65 4 1 2 6 14.0 4.5   700 
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14. C.95101 6/Mch 8200 56% 43% 01% 0   2    4 13.2 4.6 311 8500 56 44 0 0 2 4 11.2 5.0 238 
15. C81723 6/Mch 9100 P65% L31
% 
E04% 0 2 4 12.3 4.7 347 9000 55 41 04 0 3 6 12.5 5.0 320 
16. C95565 7/Mch 11000 P50% L45
% 
E04 0 2 8 15.1 5.7 373 10500 45 48 06 1 10 20 14.5 4.5 245 
17. C93890 12/fch 9000 74 20 06 0 8 26 13.3 4.2 424 8500 46 52 02 0 4 8 13.4 4.2 212 
18. C89942 10/Mch 6000 30% 61% 04% 0 2 4 12.3 4.5 380 6500 40 52 08 0 3 6 11.2 5.1 155 
19. C91098 11/Mch 8100 55% 40% 05% 0 2 4 12.4 5.0 356 7800 50 48 02 0 4 8 13.3 4.6 400 
20. C92256 6/Mch 8400 40% L50
% 
08% 0 6 14 10.4 3.4 378 8100 40 56 04   0 3 6 11.0 4.1 368 
21. C89081 4/fch 10300 46 48 04 2 2 4 13.3 4.8 564 9900 49 48 01 2 8 26 12.2 5.0 452 
22. C96967 3/mch 17300 65 32 03 0 6 14 12.8 4,9 233 10300 55 37 08 0 3 8 11.8 4.2 250 
23. C4066 3/mch 9800 60 34 06 0 4 8 13 4.5 422 9000 57 39 04 0 2 4 12.5 4.8 248 
24. D002777 5/mch 13000 65 31 4 0 2 6 11.7 4.3 1022 11000 50 48 02 0 4 8 12.4 3.5 640 
25. C8848 4/mch 12700 70 26 04 0 20 46 11.2 4.1 500 13000 59 36 05 0 4 8 11.5 4.2 144 
26. C29211 3/mch 8400 44 52 04 0 2 8 13.0 4.8 357 9000 48 50 02 0 2 4 12.4 5.0 284 
27. C14864 4/mch 6500 32 52 15 01 4 16 12.0 5.5 577 7000 44 48 08 0 2 8 12.5 4.5 312 
28. D015925 5/mch 8000 52 45 03 0 4 8 11.7 4.9 250 7900 50 40 10 0 2 6 11.4 5.0 350 
29. C97934 4/mch 6700 53 38 09 0 4 8 12.6 4 354 7000 55 41 04 0 3 6 12.8 3.8 248 
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30. C099694 5/mch 8700 55 35 10 0 2 6 12.5 4.9 1166 8000 51 44 05 0 2 8 11.4 4.5 548 
31. C92245 4/mch 10900 27 70 03 0 2 4 10.9 4.6 300 10000 53 45 01 1 2 4 11.0 4.0 186 
32. D000619 7/mch 8100 43 53 04 0 4 12 13.6 5.3 524 8000 55 42 02 1 2 8 11.5 5.2 268 
33. C86415 5/mch 8400 45 47 06 02 12 26 12.0 4.6 404 8700 50 40 10 0 10 20 12.5 4.8 214 
34. D003688 8/mch 8000 46 50 04 0 2 4 11.7 5.1 440 7900 54 44 2 0 2 6 11.5 5.0 240 
35. C71569 4/mch 13200 45 50 05 0 12 44 12.2 4.6 630 11200 50 46 4 0 4 8 11.2 4.6 510 
36. C95203 5/fch 9000 48 46 05 0 10 26 11.5 4.4 222 9100 47 50 3 0 2 6 12.0 4.0 184 
37. C30929 8/mch 7100 49 46 05 0 2 6 13.5 4.8 350 8000 50 45 5 0 4 8 12.5 4.5 235 
38. C93409 4/fch 8700 45 50 05 0 4 10 11.3 4.6 532 8500 55 43 2 0 2 6 12.0 4.4 326 
39. C97644 6/mch 8600 34 54 12 0 4 24 13.0 4.9 778 9000 45 55 0 1 2 6 12.5 4.5 454 
40. D014815 4/mch 9000 45 53 02 0 2 6 10.1 4.7 255 8900 54 43 3 0 2 4 11.4 5.0 350 
 
 
P- Polymorphs, L- Lymphocytes, E-Eosinophil, M- Monocytes 
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6. DISCUSSION 
“Valikanam” is a most common infectious disease of respiratory tract of 
childhood. Valikanam more or less resembles upper respiratory tract infections in modern 
literature. The disease is characterized by fever, cough, with or without expectoration,lack 
of appetite..  
In the present study, forty cases were treated in the outpatient and inpatient 
department, according to clinical features mentioned in textbook of Balavagadam.  
The diagnosis is based on clinical observation and laboratory investigations.  
The diagnosis were confirmed and treated with the drug “Sathaveri kirudham” and 
clearly observed.  
This study evaluates the effect of “Sathaveri kirudham” in relieving the symptoms 
of Valikanam.  
CLINICAL REVIEW 
· Age: 
 In the present study, maximum number of patients were in the age group of 3-
5yrs (42.5%) and 6-8years (32.5%) and 9-12 yrs(25%) 
· Sex:  
                         Out of 40 patients 20 patients were male children and 20 patients were 
female children. In distribution of sex it was observed that there was no predominance 
among the boys and girls. 
· Seasonal Variation:  
Rainy season was the triggering factor in aggravation of the disease valikanam 
and was observed in 62.5% of patients in koothir kalam. kanam is highly influenced by 
seasonal variations. 
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· Food habits: 
 According to food habits 36(90%) of cases had mixed diet, and 4(10%) 
had vegetarian diet. The highest incidence of cases was observed in mixed diet of food 
habits. 
· Vali (Vatham) 
Due to the derangement of different vatha the following symptoms occur. Pranan 
was affected in 100% cases and causes cough and wheezing. Abanan was affected in 40% 
and causes dysuria. Samanan was affected in 100% cases and causes loss of appetite. 
Uthanan was affected in 100% of cases and causes cough, Kirukaran was affected in 
100% and causes cough. And Devathathan was affected in affected in 37.5% cases and 
causes malaise. 
· Azhal (Pitham) 
Due to the derangement of Pitham the following symptoms occur. Analagam was 
affected 100% and causes poor appetite. Ranjakam was affected 57.5% and causes 
reduced haemoglobin. Saathakam was affected 100% and causes fatigue and malaise. 
Pirasakam was affected 57.5% and causes pallor of skin. 
· Iyyam (Kabam) 
Deranged Avalambagam was affected 100% and causes cough Klethagam was 
affected 100% and causes poor appetite.  
· Ezhu udarkattugal 
In Ezhu udal kattukal, Saram was affected 100% and causes malaise, fatigue., 
Seneer was affected 55% causes anaemia, anorexia and generalized weakness of the 
body. 
· Envagai thervugal 
 According to this study, 
Naa was affected in 57.5% of cases (coated, and pallor)  
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Vizhi were affected in 57.5% of cases (pallor),  
Sparisam was affected in 50% 0f cases (raised temperature) 
Moothiram was affected in 40% of cases. 
· Naadi: 
 Vathapitham was observed in 85 % of cases,  
Pithavatham was observed in 10% of cases,  
Pithakabam was observed in 5% of cases. 
According to naadi, high Distribution observed in vali Azhal, Azhal vali and 
Azhal iyyam naadi. In siddha literature, the character of vali Azhal is mainly constipation, 
poor appetite, abdominal pain, indigestion and nausea.  
· Neerkuri 
Regarding moothiram, neerkuri showed straw coloured urine in all cases. 
· Neikuri 
In the present study, 57.5% of patient had vatha neikuri, 22.5% was observed as 
pitha neikuri and 20% was observed as kaba neikuri. According to this neikuri, vadham 
was dominately affected. 
· Distribution according to clinical presentation 
 Of  the 40 patients of kanam in the present clinical trial,  
All (100%) had Throat irritation, Lack of appetite, Cough  
Rumbling noise in stomach was reported in 47.5%,  
Excessive thirst in 50%,  
Fever in 50%,  
Dysuria was seen in 40%. 
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 The clinical improvements were accurately noted and further follow up was made 
in outpatient department. 
· Laboratory investigations 
Most of cases were had increasedWBC and AEC, reduced hemoglobin level. 
Sputum for AFB negative for all cases. 
· Biochemical analysis 
The Bio chemical analysis of trial medicines showed the presence of calcium and 
ferrous iron, phosphate, magnesium, sodium,. Ferrous iron is more soluble and therefore 
more readily absorbed. Iron helps in increasing the haemoglobin level of blood. Calcium 
is essential for growth, as it plays an important role in the formation of bones and 
development of teeth.  
DRUG REVIEW 
The trial medicine chosen for treatment of Valikanam was “SATHAVERI 
KIRUDHAM”. The ingredients of this drug have the property of controlling Valikanam.   
The pharmacological studies already reported on the individual drugs also favour 
its effect in disease of upper respiratory tract illness as given below: 
Thaneer vitan kizhangu, Ellakkai have a potent anti bacterial activity, antipyretic 
activity and antitussive 
Thannervitan kizhangu have effective immune modulator activity. 
Parangi pattai  have a effective anti inflammatory  
Thaneervitan kizhangu,ellakkai have mainly an anti pyretic action and it reduces 
the temperature and vitalizes the derranged humour. 
The results of the study suggest that treatment with SATHAVERI KIRUDHAM 
has significant improvement in patients of Valikanam. 
Out of the 40 cases, the signs and symptoms were good in 62.5% of cases, 
moderate in 25% of cases, mild in 12.5%. These results were based on the clinical 
improvements. 
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7.  SUMMARY 
Patients attending the OPD, IPD of NIS having the compliants of Valikanam 
diagnosed clinically and the patients were observed for clinical diagnosis, laboratory 
diagnosis. 
Classical symptoms of Valikanam with emphasis to symptoms of upper 
respiratory tract infection like Rumbing noise in stomach, Mild Fever, Cough, Thirst, 
Dysuria, Throat irritation, lack of appetite  
Clinical diagnosis of Valikanam was done on the basis of clinical features 
described in Balavagadam text. 
Laboratory diagnosis was done by modern scientific  methods of examinations. 
Diagnosis has been made based on the specially prepared proforma, including all 
clinical signs and symptoms of the disease, in which detailed history had been taken 
The signs, symptoms, and etiopathogenesis of upper respiratory illlness explained 
in modern diagnosis have lot of similarities with the disease entity Valikanam. 
The medicine chosen for clinical treatment and management of valikanam is 
Sathaveri kirudham internally two times in a day for 20 days.   
All the patients were kept under strict dietary control during the treatment. The 
observation on effect of therapy was encouraging. 
The clinical efficacy of the drug was analyzed statistically on all the symptoms 
mentioned in the assessment criteria. The observation made during the clinical study 
showed that the trail drug Sathaveri kirudham was clinically effective.  
In quantitative analysis, the trial medicine Sathaveri kirudham had calcium,ferrous 
iron, phosphate, sodium and magnesium 
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8. CONCLUSION 
 All the 40 patients of Valikanam were treated with Sathaveri kirudham internally 
two times in a day. 
The ingredients of Sathaveri kirudham are feasible and useful; these compounds 
may serve as potentially useful drug at a lower cost. 
The medicine has many properties to control the signs and symptoms of 
valikanam. During the course of treatment, no adverse interactions were observed. 
Clinical results were found to be significant good improvement was found in 
62.5% of cases, moderate in 25% of cases, mild in 12.5% of cases. 
Because of the efficient results clinically, the study may be carried over to further 
researches and it may motivate the upcoming generation to manage the disease 
Valikanam through the siddha medicine and also this study throw new glitters for the 
Siddha Medicine. 
The present clinical study has established that Sathaveri kirudham is having good 
result in reducing the majority of symptoms of the Valikanam.  
This has, in turn, provided a golden opportunity for new drug established in the 
management of Valikanam. 
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STATISTICAL ANALYSIS 
All collected data were entered into computer using MS Excel software. The data entry 
was cross-checked manually with CRF. The data was analyzed using SPSS version 18.0 software. 
The probability value 0.05 was taken as significant level. Paired‘t’ test was employed to 
determine the significance of blood sugar at before and after treatment.  
Mean ±Standard deviation of clinical features (CF) of Valikanam at - Before and after 
treatment  
CF –  Before treatment  4.90 ±.744  t = 27.538, p <0.0001  
 Significant 
CF –  After treatment  0.53 ±.599 
 
The average clinical features of Valikanam at the start of treatment and after the treatment 
were 4.90 and 0.53 respectively.   
There is statistically significant difference between before and after treatment of clinical 
features of Vaikanam (p<0.0001). 
Mean ±Standard deviation of AEC - Before and after treatment  
AEC Before treatment  580.45± 217.247  t = 5.659, p <0.0001  
 Significant 
AEC After treatment 460.00±.118.347 
 
The average AEC at the start of treatment and after the treatment were 580.45and 460.00 
respectively.   
 There is statistically significant difference between before and after treatment of AEC 
(p<0.0001). 
Mean ±Standard deviation of Hemoglobin (Hb) before and After treatment  
 Hb –  Before treatment  9.500 ± 1.62267 t = -3.139, p <0.0003  
Significant 
Hb - After treatment 10.045  ±1.1241 
The average Haemoglobin at the start of treatment and after the treatment was 9.500 and 
10.045 respectively. There is statistically significant difference between before and after treatment 
of Hemoglobin (p<0.0003). 
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9. ANNEXURES 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC DISORDER  
AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
Form 1- SCREENING   
1.  S.l. No:    2. OP/ IP No:                           3.Name:          
4.Age:    5.Gender:   6.Date of Enrollment:       
7.  Date of completion: 8.Informant:    9.Reliablity:    
INCLUSION CRETERIA: 
              YES        NO 
Age: between 3-12 years 
Cough     
Irritant sensation in throat        
Rumbling in   stomach                 
Excessive thirst        
Fever     
 Lack of appetite           
Dysuria 
EXCLUSION CRITERIA: 
Pneumonia   
Jaundice   
Congenital heart diseases 
Acute severe asthma 
 
Signature of Lecturer:    signature of Principal Investigator 
Signature of HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600047. 
 
 
 PRECLINICAL AND CLINICAL STUDY ON “VALI KANAM-A PEDIATRIC    
    DISORDER  AND THE DRUG OF CHOICE IS SATHVERI KIRUDHAM 
CONSENT FORM 2 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent/guardian 
Signature  _________________ 
Date   _________________ 
Name  _________________ 
 
CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose 
of the clinical trial, and the nature of drug treatment and follow-up including the 
laboratory investigations to be performed to monitor and safeguard my son/daughter body 
functions. 
 I am aware of my right to opt  my son/daughter out of the trail at any time during 
the course of the trail without having to give the reasons for doing so.  
 I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the clinical trial of ‘SATHAVERI KIRUDHAM for the  
treatment of ‘VALI KANAM’  
 
Date :       Signature  __________________ 
 
      Name   __________________ 
 
Date :       Signature of witness  __________________ 
 
      Name   __________________ 
 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC 
DISORDER AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
FORM 3 PROFORMA 
Demographic data 
 Patient Id : OP/IP No. Visit Date : (__/__/____) 
Name :  
Age    :  
Gender                Male             Female Date Of Birth : (__/__/____) 
Father/ Mother /Guardian Name : 
 
 
Fathers Occupation : 
 
 
Fathers Monthly  Income : 
 
 
Religion : 
 
 
 
Socioeconomic Status : 
 
 
Patient Informant : 
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Postal Address 
 
 
 
 Contact No : 
 
 
1. Complaints and Duration 
 
2. Present illness  
History of Past Illness  
History /Symptoms/Signs  Yes  No  If, Yes Details 
Any Similar Complains  
Bronchial Asthma 
Dust Allergy 
 Hospitalization 
Any other        _____________ 
Family History 
Any Hereditary/ Familial Disease                      Yes                      No 
If Yes, Details-------- 
Immunisation History  
Proper Immunization given  Yes                     No           ................................................. 
Food habits: 
1. Veg  2. Non-Veg  3. Mixed 
General assessment 
1. Picca  
2. Nail biting 
3. Bowel movements 
General Examination 
1. Pallor    YES  NO 
2. Jaundice   YES  NO 
3. Cyanosis   YES  NO 
4. Clubbing   YES  NO 
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5. Pedal oedema   YES  NO 
6. Lymph adenopathy  YES  NO 
Vital signs:- 
1. Pulse rate / mint 
2. Heart rate / mint 
3. Respiratory Rate / mint 
4. Temperature 
Anthropometry:- 
          Height 
          Weight 
  Respiratory system 
a)     Inspection: 
Shape –                   :  Normal              Barrel-Shaped            Pigeon chest 
Shoulder Drooping:   Absent               Present 
 Intercostals spaces:   Normal           Bulge              Introin 
 Spine                     :  Normal            Kyphosis             Scoliosis 
 Supraclavicular fossae: Normal           Flattening              Hollowing 
 Position of mediastinum: 
 Traile’s sign:   Present               Absent 
 Apical impulse-------- 
b) PALPATION: 
Tenderness                  Yes No 
             If yes___________ 
Tactile vocal Fremitus: Normal and equal   
 Increased 
 Decreased 
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  C)  Percussion:         
Percussion on all over area:             Normal                     
        Hyper resonance                                                            
        Dullness 
D)   Auscultation: 
Intensity of breath sounds: Normal/decreased/increased __________ 
Adventitious sounds 
 Wheeze   Crepitations  Rub  None of above  
Vocal resonance: Normal/ Increased/ Decreased ______________ 
Other systems:   Normal  Affected 
Cardio vascular system: 
Gastro intestinal system: 
Musculo skeletal system:  
Central nervous system: 
Endocrine system: 
Clinical assessment:           YES        NO 
Cough        
Irritant sensation in throat        
Rumbling in   stomach                
Excessive thirst        
Fever     
 Lack of appetite         
Dysuria 
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Nilam:-  
Kurinji  Mullai  Marutham      Neithal   Paalai 
Kaala Iyalbu:-  
 Kaarkalam    Koothirkaalam  Munpanikaalam  
 Pinpanikaalam            Illavenirkaalam          Muthuvenirkaalam 
Yaakai 
 Vatham          Vatha Pitham           Vatha Kabam 
 Pitham    Pitha vatham   Pitha Kabam 
 Kabam             Kaba Vatham   Kaba Pitham 
Gunam  
 Sathuvam   Rasatham   Thamasam 
Pori / Pulangal 
  Normal Affected  Normal Affected     Remarks 
Mei / unarvu 
Vaai / suvai  
Kan / parvai  
Mooku / natram 
Sevi / olli 
Kanmendhirium / Kanmavidayam 
       Normal     Affected       Normal            Affected Remarks 
Kai / dhanam 
Kaal / ghamanam 
Vaai / vaku 
Eruvai / visarkam 
Karuvai / anantham 
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Uyir Thathukkal 
Vatham: 
   Normal   Affected  Remarks 
Pranan  
Abanan 
Viyanan  
Uthanan 
Samanan 
Nagan  
Koorman 
Kirukaran  
Devathathan   
Dhanajeyan      
Pitham  
   Normal Affected  Remarks 
Analam  
Ranjagam    
Saathagam   
Alosagam  
Prasagam 
Kabam  
   Normal Affected  Remarks 
Avalambagam    
Kilethagam   
Pothagam  
Tharpagam   
Samthigam  
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Udalthathukkal 
   Normal Affected  Remarks 
Saaram 
Senneer  
Oon  
Kozhuppu 
Enbu 
Moolai 
Sukilam / Suronitham   
Envagai Thervugal  
                            Normal  Affected  Remarks 
Naa  
 Niram 
 Thanmai 
 Suvai 
Niram   
Mozhi   
Vizhi  
 Niram 
 Thanmai 
 Parvai 
Sparisam  
Malam 
 Niram   Normal Affected 
 Nurai   Normal Affected 
 Elagal   Normal Affected 
 Erugal   Normal Affected 
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Moothiram 
 Neerkuri:       Niram   Normal Affected 
  Edai   Normal Affected  
  Nurai             Normal  Affected 
  Manam            Normal  Affected  
  Enjal Neikuri  Normal Affected   
Neikuri: 
  Vatham  
  Pitham 
  Kabam 
  Others 
Naadi: 
Thani Nadi 
       Vadham       pitham    kabam 
Thontha Nadi 
           Vatha pitham          Pitha vatham      Pitha kabam Kaba pitham 
Thoda Nadi 
 Vatha kabam          Kaba vatham 
Mukkutra Nadi 
Diagnosis   ----------------------------------------   
Admitted to trial: 1. Yes    2. No 
 If yes, S. No:  1.IP   2.OP 
Diagnosis: 
 DRUGS ISSUED:_____________ 
 Date  : ___________________     
 Station : ___________________  
Date:              Signature Of Principal Investigator
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                                NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL ,CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC 
DISORDER AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
1.  S.l. No:        2. OP/ IP No:                      3.Name:                                                   
4.Age:           5.Gender:   6.Date of Enrollment:       
7. Date of completion:       8.Informant:   9.Reliablity:                  
Form IV - LABORATORY INVESTIGATIONS  
     
 
  
 
 
ROUTINE BLOOD 
INVESTIGATIONS 
NORMAL 
VALUES 
 
BEFORE 
TMT 
Date: 
 
AFTER TMT 
Date: 
Hb ( gms%)  11.5 – 14.5    
T.RBC (milli /cu.mm)        4-4.9   
 
ESR (mm) 
½ hr. 0- 4   
1 hr.        0-13   
T.WBC (milli /cu.mm) 5000-14500   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
ABSOLUTE 
OESENOPHIL 
COUNT 
440 cells/cu m.m   
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Date:                                                Signature Of Principal Investigator
Urine Investigation 
Before TMT 
Date: 
After TMT  
Date: 
Albumin   
Sugar   
Deposits   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC 
DISORDER AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
1.  S.l. No:        2. OP/ IP No:                      3.Name:                                                   
4. Age:          5.Gender:   6.Date of Enrollment:       
7. Date of completion:       8.Informant:   9.Reliablity:                  
 
   Form V CLINICAL ASSESSMENT 
S.NO CLINICAL 
SYMPTOMS 
1st 
day 
7th 
day 
14th 
day 
20th 
day 
1. Cough     
2. Throat Irritation     
3. Rumbling Sound 
In Stomach 
    
4. Fever     
5. Excessive Thrist     
6. Loss Of Appetite     
7. Dysuria     
 
Date:                                  Signature Of Principal Investigator 
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FORM VI – PATIENT INFORMATION SHEET 
 
Name of Principal Investigator:…………………………………..…………………….. 
Name of the institute: National Institute of Siddha,                                        Tambaram Sanatorium,                                         Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN CLINICAL TRIAL. 
 
I, ________________________________________Studying as PG Scholar at National 
Institute of  Siddha, Tambaram Sanatorium is doing a trial on the study  
“VALI KANAM”(URTI). Around the world respiratory infection is one of the  common  in 
children. In this regard, I am in a need to ask you few questions. I will maintain confidentiality 
of your comments and data  obtained. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. Taking part 
in this study is voluntary. No compensation will be paid to you  for  taking  part in this study. 
           You can choose not to take part. You can choose not to answer a specific question.There 
is no specific benefit for you if you take part in the study. However, taking part in the study may 
be of benefit to the community, as it may help us to understand the problem of defaulters and 
potential solutions. 
             If you agree your child to be a participant in this study, he/she will be included in the 
study primarily by signing the consent form and then you will be given the internal medicine 
“SATHAVERI KIRUDHAM”(7ml BD with milk for 20 days). 
The information I am collecting in this study will remain between you and the principal 
investigator (myself). I will ask you few questions through a questionnaire. I will not write your 
name on this form. I will use a code instead.  
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.N.SARAVANAN, PG Scholar cum principal investigator of 
this study, attached to National Institute of Siddha,Chennai-47. You can also contact the 
Member-secretary of Ethics committee, National Institute Siddha,Chennai 600047, Tel no : 91-
44-22380789, for rights and participation in the study.  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC DISORDER 
AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
 1.  S.l. No:    2. OP/ IP No:                           3.Name:                                                  
4.Age:       5.Gender:   6.Date of Enrollment:       
7.  Date of completion: 8.Informant:    9.Reliablity:   
FORM VII WITHDRAWAL  
Date of trial commencement    : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal   : Yes/ No  
Long absence at reporting   : Yes/ No 
Irregular treatment     : Yes/ No 
Shift of locality      : Yes/ No 
Complication adverse reactions if any : Yes/ No 
Exacerbation of symptoms   : Yes/ No 
 Pt not willing to continue   : Yes/ No 
 
Date:       Signature Of Principal Investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC DISORDER 
AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
Form VIII – ADVERSE REACTION   
1.  S.l. No:    2. OP/ IP No:                           3.Name:                                                  
4.Age:       5.Gender:   6.Date of Enrollment:       
7.  Date of completion: 8.Informant:    9.Reliablity:   
   
Name       : 
Age       : 
Gender    : 
OPD/ IPD No    : 
Registration No    : 
Date of trial commencement  : 
Date of withdrawal from trial   : 
Description of adverse reaction  : 
 
 
Date:        Signature of Principal Investigator 
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                                            NATIONAL INSTITUTE OF SIDDHA 
                                   AYOTHIDOSS PANDITHAR HOSPITAL 
                                                     CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC DISORDER 
AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
Form IX – DRUG COMPLIANCE   
1.  S.l. No:    2. OP/ IP No:                           3.Name:                                                  
4.Age:       5.Gender:   6.Date of Enrollment:       
7.  Date of completion: 8.Informant:    9.Reliablity:   
NAME OF THE DRUG: SATHAVERI KIRUDHAM 
FORM OF THE DRUG: Liquid 
ADMINISTRATION & ADJUVANT: PER ORAL, MILK 
DOSE & DURATION: 6,7,9ml  TWICE DAILY FOR 20 DAYS  
NO. OF DRUG PACKETS GIVEN:   ______ 
NO. OF DRUG PACKETS RETURNED: _____   
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DAY DATE 
OF          
DRUG    
INTAKE 
MORNING 
  
EVENING  
  
   
DAY 1     
DAY 2    
DAY 3    
DAY 4    
DAY 5    
DAY 6    
DAY 7    
DAY 8    
DAY 9    
DAY 10    
DAY 11    
DAY 12    
DAY 13    
DAY 14    
DAY 15    
DAY 16    
DAY 17    
DAY 18    
DAY 19    
DAY 20    
   
Date:        Signature of Principal Investigator 
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                                            NATIONAL INSTITUTE OF SIDDHA 
                                   AYOTHIDOSS PANDITHAR HOSPITAL 
                                                     CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
PRECLINICAL AND  CLINICAL STUDY ON “VALI KANAM”-A PEADIATRIC DISORDER 
AND THE DRUG OF CHOICE IS SATHAVERI KIRUDHAM 
Form X – DIET FORM   
 
1.  S.l. No:    2. OP/ IP No:                           3.Name:                                                       
4.  Age:    5.Gender:    6.Date of Enrollment:      
7.  Date of completion:   8.Informant:      9.Reliablity:   
 
 
¯½× Àò¾¢Â Ó¨È¸û 
 
Ø À¡Ä¢ø Á¢ÇÌò àû,ÀÉí¸ü¸ñÎ ¸ÄóÐ ÌÊì¸×õ. 
Ø ÐÇº¢î º¡üÈ¢ø §¾ý ¸ÄóÐ ÌÊì¸×õ, 
Ø Ýô Å¨¸¸û ¦¸¡Îì¸×õ, 
Ø àÐ§Å¨Ç Ãºõ,Ð¨ÅÂø ¦¸¡Îì¸×õ, 
Ø ÌÇ¢÷îº¢Â¡É,þÉ¢ôÒ ¦À¡Õð¸¨Ç ¾Å¢÷ì¸×õ, 
Ø Ò¨¸,àº¢,ÀÉ¢¸¡üÈ¢ø ¿¼Á¡ÎÅ¨¾ ¾Å¢÷ì¸×õ 
 
Date:         Signature of Principal Investigator 
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ேதசிய சி த ம   வ நி வன  
அேயா திதாச ப  த  ம   வமைன ெச ைன-47 
ப டேம ப    ழ ைத ம   வ  ைற 
 
          சதாேவ  கி த  ப க     திறைன  க டறி   ம   வ ஆ    
 
                           ஒ  த  ப வ  
                     ஆ வாளரா  சா றள க ப ட .  
நா  இ த ம   வ ஆ ைவ றி த அைன   வ பர கைள   
ேநாயாள ய  ெப ேறா         வைகய  எ   ைர ேத  என உ தி 
அள கிேற . 
ேததி:                                                ைகெயா ப : 
இட :                                                ெபய : 
                 ேநாயாள ய  ெப ேறா  ஒ  த  ப வ  
         எ ன ட  இ த ம   வ ஆ வ  காரண ைத  ,ம  தி  த ைம 
ம    ம   வ வழி ைற  ப றி  ,இ த ம   வ ைத ெதாட    என  
 ழ ைதய  உட  இய க ைத  க காண  க  ,அதைன  பா கா க 
பய ப   ம   வ ஆ    ட  ப ேசாதைனக  ப றி   தி  தி 
அள    வைகய  ஆ   ம   வரா  வ ள கி  ற ப ட . 
         நா  இ த ம   வ ஆ வ  ேபா  காரண  எ    றாம  எ ேபா  
ேவ  மானா   எ  ழ ைதைய வ வ    ெகா    உ ைமைய 
ெத  தி  கிேற . 
         நா  எ  ைடய  த திரமாக ேத   ெச    உ ைமைய  ெகா   வள  
கண  ேநா  கான சதாேவ  கி த  ப க     திறைன க டறி   ம   வ 
ஆ     என  ழ ைதைய உ ப  த ஒ  த  அள கிேற . 
ேததி:                                               ெப ேறா  ைகெயா ப : 
இட :                                                              ெபய : 
ேததி:                                             சா சி கார  ைகெயா ப : 
இட :                                                                 ெபய : 
                                                                                                     உற  ைற: 
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